US20020102277A1 - Conserved metalloprotease epitopes - Google Patents
Conserved metalloprotease epitopes Download PDFInfo
- Publication number
- US20020102277A1 US20020102277A1 US09/988,019 US98801901A US2002102277A1 US 20020102277 A1 US20020102277 A1 US 20020102277A1 US 98801901 A US98801901 A US 98801901A US 2002102277 A1 US2002102277 A1 US 2002102277A1
- Authority
- US
- United States
- Prior art keywords
- peptide
- sequence
- amino acid
- acid sequence
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010006035 Metalloproteases Proteins 0.000 title claims description 25
- 102000005741 Metalloproteases Human genes 0.000 title claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 259
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 30
- 230000002163 immunogen Effects 0.000 claims abstract description 26
- 101710204001 Zinc metalloprotease Proteins 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims description 77
- 239000012634 fragment Substances 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 26
- 241000589513 Burkholderia cepacia Species 0.000 claims description 23
- 229960005486 vaccine Drugs 0.000 claims description 21
- 241000607626 Vibrio cholerae Species 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 244000052769 pathogen Species 0.000 claims description 11
- 102000014914 Carrier Proteins Human genes 0.000 claims description 9
- 108010078791 Carrier Proteins Proteins 0.000 claims description 8
- 241000607715 Serratia marcescens Species 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 8
- 241000589242 Legionella pneumophila Species 0.000 claims description 7
- -1 diphtheria toxoid Proteins 0.000 claims description 7
- 229940118696 vibrio cholerae Drugs 0.000 claims description 7
- 229940115932 legionella pneumophila Drugs 0.000 claims description 6
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 5
- 241000607265 Vibrio vulnificus Species 0.000 claims description 5
- 230000001717 pathogenic effect Effects 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 241000607528 Aeromonas hydrophila Species 0.000 claims description 4
- 241000193738 Bacillus anthracis Species 0.000 claims description 4
- 241000193155 Clostridium botulinum Species 0.000 claims description 4
- 241000193449 Clostridium tetani Species 0.000 claims description 4
- 241000186779 Listeria monocytogenes Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 241001293418 Mannheimia haemolytica Species 0.000 claims description 4
- 241000194023 Streptococcus sanguinis Species 0.000 claims description 4
- 229940065181 bacillus anthracis Drugs 0.000 claims description 4
- 108010049048 Cholera Toxin Proteins 0.000 claims description 3
- 102000009016 Cholera Toxin Human genes 0.000 claims description 3
- 101710082714 Exotoxin A Proteins 0.000 claims description 3
- 101710116435 Outer membrane protein Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 2
- 241000606790 Haemophilus Species 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 2
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 229960000814 tetanus toxoid Drugs 0.000 claims description 2
- 241000194032 Enterococcus faecalis Species 0.000 claims 3
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 79
- 108010067372 Pancreatic elastase Proteins 0.000 abstract description 56
- 102000016387 Pancreatic elastase Human genes 0.000 abstract description 56
- 235000001014 amino acid Nutrition 0.000 description 77
- 102000035195 Peptidases Human genes 0.000 description 40
- 108091005804 Peptidases Proteins 0.000 description 40
- 239000004365 Protease Substances 0.000 description 40
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 29
- 238000002965 ELISA Methods 0.000 description 20
- 230000002788 anti-peptide Effects 0.000 description 20
- 230000001580 bacterial effect Effects 0.000 description 18
- 108091005658 Basic proteases Proteins 0.000 description 17
- 108090001109 Thermolysin Proteins 0.000 description 17
- 101000871876 Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961) Hemagglutinin/proteinase Proteins 0.000 description 17
- 230000003053 immunization Effects 0.000 description 17
- 238000002649 immunization Methods 0.000 description 17
- 241000700159 Rattus Species 0.000 description 15
- 201000003883 Cystic fibrosis Diseases 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 239000002671 adjuvant Substances 0.000 description 12
- 238000003119 immunoblot Methods 0.000 description 12
- 230000003472 neutralizing effect Effects 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 229940098773 bovine serum albumin Drugs 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 239000000562 conjugate Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 230000007170 pathology Effects 0.000 description 8
- 230000002797 proteolythic effect Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102100021277 Beta-secretase 2 Human genes 0.000 description 6
- 101710150190 Beta-secretase 2 Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000003622 mature neutrocyte Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000193389 Bacillus thermoproteolyticus Species 0.000 description 3
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 3
- ALCAUWPAMLVUDB-FXQIFTODSA-N Glu-Gln-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ALCAUWPAMLVUDB-FXQIFTODSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HQLSBZFLOUHQJK-STECZYCISA-N Ile-Tyr-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HQLSBZFLOUHQJK-STECZYCISA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 101710194807 Protective antigen Proteins 0.000 description 3
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 3
- 241000607720 Serratia Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000863 peptide conjugate Substances 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- DFVFTMTWCUHJBL-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-6-methylheptanoate Chemical compound CC(C)CC(N)C(O)CC(O)=O DFVFTMTWCUHJBL-UHFFFAOYSA-N 0.000 description 2
- YHKANGMVQWRMAP-DCAQKATOSA-N Ala-Leu-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YHKANGMVQWRMAP-DCAQKATOSA-N 0.000 description 2
- YNSGXDWWPCGGQS-YUMQZZPRSA-N Arg-Gly-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O YNSGXDWWPCGGQS-YUMQZZPRSA-N 0.000 description 2
- HPBNLFLSSQDFQW-WHFBIAKZSA-N Asn-Ser-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O HPBNLFLSSQDFQW-WHFBIAKZSA-N 0.000 description 2
- CSEJMKNZDCJYGJ-XHNCKOQMSA-N Asp-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N)C(=O)O CSEJMKNZDCJYGJ-XHNCKOQMSA-N 0.000 description 2
- YNCHFVRXEQFPBY-BQBZGAKWSA-N Asp-Gly-Arg Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N YNCHFVRXEQFPBY-BQBZGAKWSA-N 0.000 description 2
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VNTGPISAOMAXRK-CIUDSAMLSA-N Gln-Pro-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O VNTGPISAOMAXRK-CIUDSAMLSA-N 0.000 description 2
- ATRHMOJQJWPVBQ-DRZSPHRISA-N Glu-Ala-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ATRHMOJQJWPVBQ-DRZSPHRISA-N 0.000 description 2
- LRQXRHGQEVWGPV-NHCYSSNCSA-N Gly-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN LRQXRHGQEVWGPV-NHCYSSNCSA-N 0.000 description 2
- ICUTTWWCDIIIEE-BQBZGAKWSA-N Gly-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN ICUTTWWCDIIIEE-BQBZGAKWSA-N 0.000 description 2
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- CCHSQWLCOOZREA-GMOBBJLQSA-N Ile-Asp-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O)N CCHSQWLCOOZREA-GMOBBJLQSA-N 0.000 description 2
- 108010028921 Lipopeptides Proteins 0.000 description 2
- JQECLVNLAZGHRQ-CIUDSAMLSA-N Met-Asp-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(N)=O JQECLVNLAZGHRQ-CIUDSAMLSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- YSGAPESOXHFTQY-IHRRRGAJSA-N Tyr-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N YSGAPESOXHFTQY-IHRRRGAJSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- KRAHMIJVUPUOTQ-DCAQKATOSA-N Val-Ser-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KRAHMIJVUPUOTQ-DCAQKATOSA-N 0.000 description 2
- 241000544286 Vibrio anguillarum Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000021235 carbamoylation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 108010009355 microbial metalloproteinases Proteins 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001662 opsonic effect Effects 0.000 description 2
- 230000003571 opsonizing effect Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- NYBZAGXTZXPYND-GBIKHYSHSA-N pyochelin I Chemical compound S1C[C@@H](C(O)=O)N(C)[C@H]1[C@@H]1N=C(C=2C(=CC=CC=2)O)SC1 NYBZAGXTZXPYND-GBIKHYSHSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- JPOKAKNGULMYHZ-UILVTTEASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 JPOKAKNGULMYHZ-UILVTTEASA-N 0.000 description 1
- KMOUUZVZFBCRAM-OLQVQODUSA-N (3as,7ar)-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1C=CC[C@@H]2C(=O)OC(=O)[C@@H]21 KMOUUZVZFBCRAM-OLQVQODUSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- KFDPCYZHENQOBV-UHFFFAOYSA-N 2-(bromomethyl)-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1CBr KFDPCYZHENQOBV-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical class O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- IXTLVPXCZJJUQB-VYJQSIGYSA-N 4-[[1-[[(2r)-1-[[(2s)-5-(diaminomethylideneamino)-1-[[(2r)-1-[[(2s)-5-[formyl(hydroxy)amino]-1-[[(3s,6s,9s,12s)-9-[3-[formyl(hydroxy)amino]propyl]-3,6-bis[(1r)-1-hydroxyethyl]-2,5,8,11-tetraoxo-1,4,7,10-tetrazacyclohexadec-12-yl]amino]-1-oxopentan-2-yl]am Chemical compound C1CCCNC(=O)[C@H]([C@H](O)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCN(O)C=O)NC(=O)[C@H]1NC(=O)[C@H](CCCN(O)C=O)NC(=O)[C@@H](CO)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CO)NC(=O)C1N(C=2C(=CC(O)=C(O)C=2)C=C2NC(=O)CCC(O)=O)C2NCC1 IXTLVPXCZJJUQB-VYJQSIGYSA-N 0.000 description 1
- JAJQQUQHMLWDFB-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-5-phenylpentanoate Chemical compound OC(=O)CC(O)C(N)CC1=CC=CC=C1 JAJQQUQHMLWDFB-UHFFFAOYSA-N 0.000 description 1
- 101710131943 40S ribosomal protein S3a Proteins 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 1
- XCVRVWZTXPCYJT-BIIVOSGPSA-N Ala-Asn-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N XCVRVWZTXPCYJT-BIIVOSGPSA-N 0.000 description 1
- FXKNPWNXPQZLES-ZLUOBGJFSA-N Ala-Asn-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O FXKNPWNXPQZLES-ZLUOBGJFSA-N 0.000 description 1
- KQESEZXHYOUIIM-CQDKDKBSSA-N Ala-Lys-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KQESEZXHYOUIIM-CQDKDKBSSA-N 0.000 description 1
- XSTZMVAYYCJTNR-DCAQKATOSA-N Ala-Met-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O XSTZMVAYYCJTNR-DCAQKATOSA-N 0.000 description 1
- QRIYOHQJRDHFKF-UWJYBYFXSA-N Ala-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 QRIYOHQJRDHFKF-UWJYBYFXSA-N 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- KMSHNDWHPWXPEC-BQBZGAKWSA-N Arg-Asp-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KMSHNDWHPWXPEC-BQBZGAKWSA-N 0.000 description 1
- URAUIUGLHBRPMF-NAKRPEOUSA-N Arg-Ser-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O URAUIUGLHBRPMF-NAKRPEOUSA-N 0.000 description 1
- JQHASVQBAKRJKD-GUBZILKMSA-N Arg-Ser-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N JQHASVQBAKRJKD-GUBZILKMSA-N 0.000 description 1
- FOWOZYAWODIRFZ-JYJNAYRXSA-N Arg-Tyr-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCN=C(N)N)N FOWOZYAWODIRFZ-JYJNAYRXSA-N 0.000 description 1
- LFWOQHSQNCKXRU-UFYCRDLUSA-N Arg-Tyr-Phe Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 LFWOQHSQNCKXRU-UFYCRDLUSA-N 0.000 description 1
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 1
- FMNBYVSGRCXWEK-FOHZUACHSA-N Asn-Thr-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O FMNBYVSGRCXWEK-FOHZUACHSA-N 0.000 description 1
- SVABRQFIHCSNCI-FOHZUACHSA-N Asp-Gly-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SVABRQFIHCSNCI-FOHZUACHSA-N 0.000 description 1
- 101000585552 Bacillus anthracis Protective antigen Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- RMOCFPBLHAOTDU-ACZMJKKPSA-N Gln-Asn-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RMOCFPBLHAOTDU-ACZMJKKPSA-N 0.000 description 1
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GWCRIHNSVMOBEQ-BQBZGAKWSA-N Gly-Arg-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O GWCRIHNSVMOBEQ-BQBZGAKWSA-N 0.000 description 1
- GNPVTZJUUBPZKW-WDSKDSINSA-N Gly-Gln-Ser Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GNPVTZJUUBPZKW-WDSKDSINSA-N 0.000 description 1
- QPCVIQJVRGXUSA-LURJTMIESA-N Gly-Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QPCVIQJVRGXUSA-LURJTMIESA-N 0.000 description 1
- FULZDMOZUZKGQU-ONGXEEELSA-N Gly-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN FULZDMOZUZKGQU-ONGXEEELSA-N 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- HXKZJLWGSWQKEA-LSJOCFKGSA-N His-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1 HXKZJLWGSWQKEA-LSJOCFKGSA-N 0.000 description 1
- RAVLQPXCMRCLKT-KBPBESRZSA-N His-Gly-Phe Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RAVLQPXCMRCLKT-KBPBESRZSA-N 0.000 description 1
- DLTCGJZBNFOWFL-LKTVYLICSA-N His-Tyr-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CN=CN2)N DLTCGJZBNFOWFL-LKTVYLICSA-N 0.000 description 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
- 101001010513 Homo sapiens Leukocyte elastase inhibitor Proteins 0.000 description 1
- HDODQNPMSHDXJT-GHCJXIJMSA-N Ile-Asn-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O HDODQNPMSHDXJT-GHCJXIJMSA-N 0.000 description 1
- WXLYNEHOGRYNFU-URLPEUOOSA-N Ile-Thr-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N WXLYNEHOGRYNFU-URLPEUOOSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- CUXRXAIAVYLVFD-ULQDDVLXSA-N Leu-Arg-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CUXRXAIAVYLVFD-ULQDDVLXSA-N 0.000 description 1
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 1
- WFCKERTZVCQXKH-KBPBESRZSA-N Leu-Tyr-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O WFCKERTZVCQXKH-KBPBESRZSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- IYXDSYWCVVXSKB-CIUDSAMLSA-N Met-Asn-Glu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IYXDSYWCVVXSKB-CIUDSAMLSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 101100068676 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gln-1 gene Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- JEBWZLWTRPZQRX-QWRGUYRKSA-N Phe-Gly-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O JEBWZLWTRPZQRX-QWRGUYRKSA-N 0.000 description 1
- XNQMZHLAYFWSGJ-HTUGSXCWSA-N Phe-Thr-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XNQMZHLAYFWSGJ-HTUGSXCWSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- FEPSEIDIPBMIOS-QXEWZRGKSA-N Pro-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 FEPSEIDIPBMIOS-QXEWZRGKSA-N 0.000 description 1
- FFSLAIOXRMOFIZ-GJZGRUSLSA-N Pro-Gly-Trp Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)CNC(=O)[C@@H]1CCCN1 FFSLAIOXRMOFIZ-GJZGRUSLSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 1
- NYBZAGXTZXPYND-UHFFFAOYSA-N Pyochelin I Natural products S1CC(C(O)=O)N(C)C1C1N=C(C=2C(=CC=CC=2)O)SC1 NYBZAGXTZXPYND-UHFFFAOYSA-N 0.000 description 1
- 229930186551 Pyoverdin Natural products 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- BRKHVZNDAOMAHX-BIIVOSGPSA-N Ser-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N BRKHVZNDAOMAHX-BIIVOSGPSA-N 0.000 description 1
- GHPQVUYZQQGEDA-BIIVOSGPSA-N Ser-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N)C(=O)O GHPQVUYZQQGEDA-BIIVOSGPSA-N 0.000 description 1
- WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 1
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 1
- MUARUIBTKQJKFY-WHFBIAKZSA-N Ser-Gly-Asp Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MUARUIBTKQJKFY-WHFBIAKZSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- RXUOAOOZIWABBW-XGEHTFHBSA-N Ser-Thr-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RXUOAOOZIWABBW-XGEHTFHBSA-N 0.000 description 1
- BIWBTRRBHIEVAH-IHPCNDPISA-N Ser-Tyr-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O BIWBTRRBHIEVAH-IHPCNDPISA-N 0.000 description 1
- 108090000899 Serralysin Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241001221452 Staphylococcus faecalis Species 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- DCLBXIWHLVEPMQ-JRQIVUDYSA-N Thr-Asp-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DCLBXIWHLVEPMQ-JRQIVUDYSA-N 0.000 description 1
- GKWNLDNXMMLRMC-GLLZPBPUSA-N Thr-Glu-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O GKWNLDNXMMLRMC-GLLZPBPUSA-N 0.000 description 1
- BNGDYRRHRGOPHX-IFFSRLJSSA-N Thr-Glu-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O BNGDYRRHRGOPHX-IFFSRLJSSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- AKXBNSZMYAOGLS-STQMWFEESA-N Tyr-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AKXBNSZMYAOGLS-STQMWFEESA-N 0.000 description 1
- KHCSOLAHNLOXJR-BZSNNMDCSA-N Tyr-Leu-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHCSOLAHNLOXJR-BZSNNMDCSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- BGTDGENDNWGMDQ-KJEVXHAQSA-N Val-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N)O BGTDGENDNWGMDQ-KJEVXHAQSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000244 anti-pseudomonal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- AWGTVRDHKJQFAX-UHFFFAOYSA-M chloro(phenyl)mercury Chemical compound Cl[Hg]C1=CC=CC=C1 AWGTVRDHKJQFAX-UHFFFAOYSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002901 elastaselike Effects 0.000 description 1
- 230000003246 elastolytic effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 108010075387 exoenzyme S Proteins 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108700023046 methionyl-leucyl-phenylalanine Proteins 0.000 description 1
- SJFKGZZCMREBQH-UHFFFAOYSA-N methyl ethanimidate Chemical compound COC(C)=N SJFKGZZCMREBQH-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000625 opsonophagocytic effect Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 101800002712 p27 Proteins 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108010025281 pyoverdin Proteins 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000001783 staphylolytic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 101150044170 trpE gene Proteins 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the field of immunization against bacterial diseases.
- it relates to immunization against diseases caused by bacteria which secrete zinc metalloproteases and to therapeutic vaccines for treatment of such diseases.
- Pseudomonas aeruginosa produces at least two zinc metalloproteases, elastase and alkaline protease. Elastase degrades several important biological substances including elastin, immunoglobulins, collagen, transferrin and complement components (1). Alkaline protease has been shown to degrade C1q and C3 proteins of serum complement (2) and gamma interferon (3). P. aeruginosa also secretes Las A protease, which has both elastolytic and staphylolytic activity and has some properties of a metalloprotease (4-6).
- Burkholderia (Pseudomonas) cepacia produces both a 36 kDa zinc metalloprotease (PSCP) which is immunologically related to elastase and a related 40 kDa protease (7).
- PSCP zinc metalloprotease
- thermolysin Bacillus thermoproteolyticus secretes thermolysin, a heat-stable neutral zinc metalloprotease. There is 28% sequence homology between P. aeruginosa elastase and thermolysin (8), with greater homology in certain regions, particularly around the active site. However, comparison of the three-dimensional structures of thermolysin and P. aeruginosa elastase reveals a striking similarity (9).
- Hase and Finkelstein (12,13) have demonstrated that the V. cholerae HA/protease is related to P. aeruginosa elastase.
- CF cystic fibrosis
- P. aeruginosa has been reported to be present in 60% of respiratory tract cultures from CF patients and once colonization has occurred, P. aeruginosa is difficult or impossible to eradicate (16).
- a large array of virulence factors have been identified and shown to contribute to the pathogenesis of P. aeruginosa infections. These include elastase, alkaline protease, exotoxin A, exoenzyme S, pyochelin, pyoverdin, phospholipase C, pili, outer membrane proteins, lipopolysaccharide (LPS) and alginate.
- B. cepacia is a nosocomial pathogen which has been isolated with increasing frequency from respiratory infections in CF patients over the past 20 years (15). Acquisition of B. cepacia can pose particular problems because of its resistance to many anti-pseudomonal antibiotics. For example, in one study of 55 CF patients with B. cepacia pulmonary-infection, 39 (70%) had acquired multiresistant strains (17). Once acquired, B. cepacia is nearly impossible to eradicate.
- bacterial proteases such as elastase can function to modulate the host immune system and assist the bacterium in evading host defences (20-22).
- the inventors have identified two regions of the P. aeruginosa amino acid sequence, and within these regions, two epitopes, which are recognized by antibodies which neutralise the proteolytic activity of P. aeruginosa elastase and other thermolysin-like proteases.
- Peptides corresponding to the two identified regions of amino acid sequence, and peptides comprising fragments of these sequences provide immunogenic compositions which can be administered to a host to stimulate production of neutralising antibodies and protect the host against diseases caused by pathogens which secrete thermolysin-like metalloproteases.
- Antibodies raised against the peptides of the invention also recognise serralysin-like proteases and immunization with these peptides may also be used to provide protection against pathogens secreting serralysin-like proteases.
- the invention provides a peptide comprising the amino acid sequence
- the invention provides a peptide comprising the amino acid sequence HGFTEQNSG.
- the invention provides a peptide comprising the amino sequence
- the invention provides a peptide comprising the amino acid sequence RYMDQPSRD.
- the invention provides an immunogenic composition
- the at least one active component producing an immune response when administered to a host.
- the invention provides an antibody or antiserum specific for a peptide selected from the group consisting of
- the invention provides a method for protecting a susceptible host against a disease caused by a bacterial pathogen which secretes a zinc metalloprotease.
- the invention provides a purified isolated nucleic acid molecule encoding a peptide selected from the group consisting of
- the invention provides a method of producing a vaccine comprising administering an immunogenic composition comprising at least one active component selected from the group consisting of:
- a pharmaceutically acceptable carrier to a test host to determine an amount and a frequency of administration of the active component to confer protection against a disease caused by a bacterial pathogen which secretes a zinc metalloprotease, and formulating the active component in a form suitable for administration to a host to be treated in accordance with the determined amount and frequency of administration.
- FIGS. 1A and 1B illustrate epitope mapping of a 13.9 kDa NCS-elastase fragment by peptide scanning analysis, as shown by ELISA reactions of MAb 36-6-6 (FIG. 1A) and MAb 36-6-8 (FIG. 1B) with sixty overlapping 9-mer peptides, with a two amino acid offset, encompassing the 13.9 kDa NCS-elastase fragment. Positive control peptides are indicated by asterisks.
- FIG. 2 shows a sequence comparison of P. aeruginosa elastase peptide 15 and peptide 42 with other metalloproteases.
- the regions of metalloproteases with the greatest identity to peptide 15 and peptide 42 were identified using the Pc/Gene QG Search program (Intelligenetics). Identical residues are boxed. Conservative amino acid changes are underlined.
- FIG. 3A shows an SDS-PAGE analysis of peptides resulting from the partial digestion of P. aeruginosa elastase with NCS. Peptides are stained with Coomassie blue. Lane 1: elastase digested for 1 min with NCS; Lane 2: elastase digested for 60 min with NCS; Lane 3: elastase incubated in buffer without NCS for 60 min; Lane 4: molecular mass markers: 45.5, 29.6, 18.7, 15.5, 5.9, and 2.9 kDa.
- FIG. 3B shows an immunoblot analysis of NCS-elastase fragments probed with MAb 36-6-8, an antibody to B. cepacia 36 kDa protease. Lanes are the same as in FIG. 3A.
- FIG. 4A shows an immunoblot of antiserum to peptide 15 binding to various bacterial metalloproteases: Lane 1, elastase; lane 2, molecular mass markers; lane 3 , V. cholerae HA/protease; lane 4, P. aeruginosa alkaline protease; lane 5, SMP; lane 6, thermolysin; lane 7 , B. cepacia PSCP; lane 8 , B. cepacia 40 kDa protease.
- FIG. 4B shows immunoblot of antiserum to peptide 42 binding to bacterial metalloproteases as in FIG. 4A.
- FIG. 5A shows a comparison of ELISA binding curves of peptide 15 antibodies to the following proteases:
- FIG. 5B shows a comparison of ELISA binding curves of peptide 42 antibodies to various proteases identified as in FIG. 5A.
- thermolysin-like or elastase-like group includes B. thermoproteolyticus thermolysin, P. aeruginosa elastase, PSCP and V. cholerae HA/protease.
- the serralysin-like group includes P. aeruginosa alkaline protease and Serratia marcescens protease.
- the zinc metalloproteases share a unique amino acid motif HExxH (28).
- Monoclonal antibodies raised against PSCP have been described (7,29) which neutralize the proteolytic activity of PSCP, P. aeruginosa elastase, thermolysin, and V. cholerae HA/protease but not P. aeruginosa alkaline protease nor Serratia marcescens SMP. These antibodies were used to determine which epitopes on these proteases were recognized by these broadly crossreactive antibodies.
- Peptide 15 overlaps the 337 HExxH 341 active site found in elastase. Antibody binding to the amino acid sequence 341 HGFTEQNSG 349 would explain the ability of these antibodies to neutralize elastase.
- An identical sequence is found in V. cholerae HA/protease (FIG. 2). Three of nine residues match the thermolysin sequence in the region of the HExxH motif, which may be sufficient for antibody binding and neutralization. A better match is found, however, in the region spanning residues 227-235, with four of nine residues identical to peptide 15. This region spans the Histidine at residue 231, which acts as a proton donor at the active site. Antibody binding to this epitope may be the reason that thermolysin is inactivated.
- Peptide 42 ( 395 RYMDQPSRD 403 ) is located between E 361 , which binds a zinc atom, and H 420 , which acts as a proton donor at the active site (8, 30).
- the binding of antibodies to this epitope could effectively inhibit proteolytic activity by directly blocking the active site cleft.
- a nearly identical sequence is present in V. cholerae HA/protease, with eight of nine residues identical (FIG. 2). There is less homology between elastase and thermolysin in this region.
- Two possible epitopes recognized by the antibodies are between residues 192-200 and residues 203-211 of elastase. Both epitopes match peptide 42 with three of nine residues identical. Both sequences are located between the zinc binding site and the H 231 which serves as the proton donor.
- Antibodies to peptide 15 or peptide 42 do not neutralize alkaline protease.
- the sequence with the best homology to peptide 15 spans residues 224-232 of alkaline protease, with four identical and two conserved residues (FIG. 2). This epitope is downstream of the active site and therefore, antibody binding to this site may have no effect on enzyme activity. Five other possible matches were identified with three identical residues (data not shown).
- the best sequence match to peptide 42 lies between residues 238-246 of alkaline protease with only three residues conserved. This epitope is also downstream of the active site. There is no homology in the active site region.
- Monoclonal antibodies 36-6-6 and 36-6-8 to PSCP were previously shown to crossreact also with P. aeruginosa LasA, and Bacillus anthracis protective antigen (PA) and lethal factor (LF) (29). This crossreaction might be explained by sequence homology to peptides 15 and 42. There are six possible nine-mer epitopes in Las A with three residues identical to peptide 15. There is one possible epitope in LF with five conserved residues. Two possible sites with four residues conserved and five with three residues conserved are present in PA. In terms of peptide 42, there is one possible epitope in LasA with four conserved amino acids, three possible epitopes in PA with three conserved amino acids, and seven potential epitopes in LF with three conserved residues.
- Antibody to peptide 15 and peptide 42 reacted better with nondenatured proteases in the ELISA assay than with denatured proteins on Western blots.
- the ability of the antibodies to react with proteases on Western blots appeared to correlate with the degree of sequence homology between the elastase epitopes corresponding to peptide 15 or 42. There was less of a difference in the ELISA reactions although both antisera, particularly antipeptide 42 sera, reacted most strongly with elastase and HA/protease.
- Such bacterial species include pathogens of humans and other mammals and also pathogens of other vertebrates such as fish; for example such species include strains of P. aeruginosa, B. cepacia, Vibrio cholerae, V. anguillarum, V. vulnificus, Legionella pneumophila, Staphylococcus epidermidis, and S. aureus.
- bacterial species which produce and secrete serralysin-like proteases, which may not be neutralized by antibodies stimulated by the peptides of the invention, a protective effect may nevertheless be achieved where these antibodies bind to protease molecules on the bacterial cell surface, leading to opsonic and phagocytic destruction of the bacteria.
- bacterial species include strains of S. marcescens and Aeromonas hydrophila.
- thermolysin-like proteases which may be neutralized by antibodies stimulated by the peptides of the invention
- an additional protective effect may be achieved where these antibodies bind to protease molecules on the bacterial cell surface, leading to opsonic and phagocytic destruction of the bacteria.
- Such bacterial species include strains of P. aeruginosa, B. cepacia, Vibrio cholerae, V. anguillarum, V. vulnificus, Legionella pneumophila, Staphylococcus epidermidis, and S. aureus.
- antibodies stimulated by the peptides of the invention may provide neutralizing antibodies and/or opsonophagocytic activity leading to the destruction of the bacteria.
- bacterial species include strains of Bacillus anthracis, Clostridium tetani, C. botulinum, Streptococcus sanguis, S. faecalis, Pasteurella haemolytica, and Lysteria monocytogenes.
- Immunogenic compositions suitable to be used as vaccines, may be prepared from peptide VSHGFTEQNSGLIYRGQSGGMEAF, peptide SGALRYMDQPSRDGRSIDM and fragments and analogues thereof, as disclosed herein.
- Peptides of about nine consecutive amino acids selected from the sequences VSHGFTEQNSGLIYRGQSGGMNEAF and SGALRYMDQPSRDGRSIDM, or analogues of such peptides, are preferred.
- Peptides HGFTEQNSG and RYMDQPSRD are especially preferred.
- An immunogenic composition may also be prepared from a peptide mixture, such as a mixture of peptides HGFTEQNSG and RYMDQPSRD.
- the peptide to be used as immunogen is preferably conjugated to a carrier protein to improve its immunogenicity.
- suitable carrier proteins for immunogens for human use include keyhole limpet haemocyanin, diphtheria toxoid, diphtheria toxin CRM197, tetanus toxoid, P. aeruginosa exotoxin A mutant form, cholera toxin B subunit, pertussis toxin subunits, measles virus F protein and Haemophilus PRP outer membrane protein.
- Such immunogenic compositions elicit an immune response in a treated subject which produces antibodies, including anti-peptide 15 and/or anti-peptide 42 antibodies. If the treated subject is challenged by P. aeruginosa, B. cepacia, Vibrio cholerae or other bacteria that secrete a thermolysin-like metalloprotease, the antibodies elicited by the vaccination neutralise the zinc metalloprotease of the invading organism and resist tissue destruction by the organism.
- Antibodies produced in a subject in response to vaccination with one of the peptides of the invention may also provide protection by means of bactericidal or opsonising properties.
- bacteria which have on their cell surface proteases which bind to the produced antibodies may be destroyed by opsonising and phagocytosis or by bactericidal activity in the presence of complement.
- Administration of the immunogenic compositions of the invention to a subject may be done either as a therapeutic measure after the subject has become infected with a zinc metalloprotease-producing. pathogen, or may be done as a prophylactic measure in subjects susceptible to infection with such pathogens.
- chronic infections occurring in CF, panbronchiolitis or bronchitis may be treated therapeutically.
- Subjects susceptible to infections for example cancer patients or burn patients or military personnel, may receive prophylactic immunisation.
- Vaccines containing proteins or peptides are generally well known in the art, as exemplified by U.S. Pat. Nos. 4,601,903; 4,599,231; 4,599,230; and 4,596,792; all of which references are incorporated herein by reference.
- Immunogenic compositions including vaccines may be prepared as injectables, as liquid solutions or as emulsions.
- Peptide 15 or peptide 42 or analogues or fragments thereof may be mixed with pharmaceutically acceptable excipients which are compatible with the peptides, fragments or analogues.
- excipients may include water, saline, dextrose, glycerol, ethanol, and combinations thereof.
- the immunogenic compositions and vaccines of the invention may further contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness of the vaccines.
- Immunogenic compositions and vaccines may be administered parenterally, or by injection subcutaneously or intramuscularly.
- the immunogenic compositions formed according to the present invention may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces.
- the oral, nasal, vaginal, gastrointestinal, respiratory or other mucosal route of vaccine administration may be preferred to combat infections which take place at mucosal surfaces, for example in the respiratory, digestive or urogenital tracts.
- Nasal immunization has been shown to be efficacious in generating both respiratory tract mucosal immunity and systemic immunity. Inhalation of an aerosol formulation may also be used to combat lung or respiratory tract infections.
- Delivery systems for mucosal immunization include lipid vesicles, biodegradable microcapsules, attenuated bacteria, live viral vectors and bacterial toxins or subunits thereof.
- cholera toxin B subunit may be conjugated to an -antigen for improved mucosal immunization.
- Targeting molecules such as strain B12 and fragments of bacterial toxins, are described in WO92/17167 (Biotech Australia Pty. Ltd.), and targeting monoclonal antibodies are described in U.S. Pat. No. 5,194,254 (Barber et al.).
- binders and carriers may include, for example, polyalkalene glycols or triglycerides.
- Oral formulations may include normally employed excipients such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate.
- Immunogenic compositions may take the form of solutions, aerosols, suspensions, tablets, pills, capsules, sustained release formulations or powders and may comprise 10-95% of peptide 15 or peptide 42 or an analogue or fragment of one of these peptides.
- the vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic.
- the quantity of vaccine to be administered depends on the subject to be treated, including, for example, the weight of the subject and the capacity of the subject's immune system to synthesise antibodies, and if needed, to produce a cell-mediated immune response.
- the dosage of the vaccine may also depend on the route of administration. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of micrograms of the peptides, analogues or fragments thereof. Suitable regimes for initial administration and booster doses of vaccine are also well known in the art. These include an initial administration followed by subsequent administrations.
- Nucleic acid molecules encoding the peptides of the present invention may also be used for immunization.
- DNA in a plasmid vector may be administered directly, in saline, by injection, preferably by intramuscular injection, for genetic immunization. It is believed that the DNA is expressed in vivo to give the encoded peptide antigen which stimulates an immune response.
- DNA may also be administered by constructing a live vector such as Salmonella, BCG, adenovirus, poxvirus, vaccinia or poliovirus including the DNA.
- Nucleic acid molecules encoding the peptides of the invention may be obtained, for example, by excising the relevant portions of P. aeruginosa elastase DNA, clones of which are available from the group which obtained this sequence (8).
- nucleic acid molecule encoding a peptide of the invention conjugated to a selected carrier protein may be used for immunization, as described above.
- the immunogenicity of antigens can be significantly improved if they are co-administered with adjuvants.
- adjuvants may be employed which not only enhance but selectively modulate the type of immune response to the administered antigen; for example monophosphoryl lipid A (MPL) favours a TH1 type response, while QS21 (Cambridge Biotech) favours a cytotoxic T cell response.
- Adjuvants or immunostimulatory agents are known to improve host immune responses to vaccines.
- Intrinsic adjuvants such as lipopolysaccharides, normally are the components of the killed or attenuated bacteria used as vaccines.
- Aluminum hydroxide and aluminum phosphate are adjuvants commonly used in human and veterinary vaccines.
- An adjuvant should be non-toxic, capable of stimulating a sustained immune response and compatible with the immunogenic composition employed as a vaccine.
- U.S. Pat. No. 4,855,283 granted to Ockhoff et al. on Aug. 8, 1989 which is incorporated herein by reference teaches glycolipid analogues, including N-glycosylamide, N-glycosylureas and N-glycosylcarbamates, each of which is substituted in the sugar residues by an amino acid, as immuno-modulators or adjuvants.
- Lockhoff et al. (33) reported that N-glycolipid displaying structural similarities to the naturally occurring glycolipids, such as glycosphingolipids and glycoclycerolipids, are capable of eliciting strong immune responses both to herpes simplex virus and to pseudorabies virus.
- Some glycolipids have been synthesised from long chain-alkylamines and fatty acids that are linked directly with the sugars through the anomeric carbon atom, to mimic the functions of the naturally occurring lipid residues.
- Wiesmuller describes a peptide with a sequence homologous to a foot-and-mouth disease viral protein coupled to an adjuvant tripalmityl-s-glyceryl-cysteinylserylserine, being a synthetic analogue of the N-terminal part of the lipoprotein from Gram negative bacteria.
- Peptides in accordance with the invention or fragments or analogues thereof may be prepared by any suitable peptide synthetic method.
- Chemical synthesis may be employed, for example standard solid phase peptide synthetic techniques may be used.
- standard solid phase peptide synthesis peptides of varying length can be prepared using commercially available equipment. This equipment can be obtained from Applied Biosystems (Foster City, Calif.).
- the reaction conditions in peptide synthesis are optimized to prevent isomerization of stereochemical centres, to prevent side reactions and to obtain high yields.
- the peptides are synthesized using standard automated protocols, using t-butoxycarbonyl-alpha-amino acids, and following the manufacturer's instructions for blocking interfering groups, protecting the amino acid to be reacted, coupling, deprotecting and capping of unreacted residues.
- the solid support is generally based on a polystyrene resin, the resin acting both as a support for the growing peptide chain, and as a protective group for the carboxy terminus. Cleavage from the resin-yields the free carboxylic acid.
- Peptides are purified by HPLC techniques, for example on a preparative C18 reverse phase column, using acetonitrile gradients in 0.1% trifluoroacetic acid, followed by vacuum drying.
- Peptides may also be produced by recombinant synthesis.
- a DNA sequence encoding the desired peptide is prepared, for example by cloning the required fragment from the DNA sequence encoding elastase, and subcloning into an expression plasmid DNA.
- Suitable mammalian expression plasmids include pRC/CMV from Invitrogen Inc.
- the gene construct is expressed in a suitable cell line, such as a Cos or CHO cell line and the expressed peptide is extracted and purified by conventional methods. Suitable methods for recombinant synthesis of peptides are described in “Molecular Cloning” (Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory Press, 1989).
- Analogues of a peptide may be prepared by similar synthetic methods.
- the term “analogue” extends to any functional and/or chemical equivalent of peptide 15 or peptide 42 and includes peptides having one or more conservative amino acid substitutions, peptides incorporating unnatural amino acids and peptides having modified side chains.
- side chain modifications contemplated by the present invention include modification of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH 4 ; amidation with methylacetimidate; acetylation with acetic anhydride; carbamylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6, trinitrobenzene sulfonic acid (TNBS); alkylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5′-phosphate followed by reduction with NaBH 4 .
- amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH 4 ; amidation with methylacetimidate; acetylation with acetic anhydride; carbamylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6, trinitrobenzene sulfonic acid (TNBS
- the guanidino group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2, 3-butanedione, phenylglyoxal and glyoxal.
- the carboxyl group may be modified by carbodiimide activation via -acylisourea formation followed by subsequent derivatisation, for example, to a corresponding amide.
- Sulfhydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulfonic acid, phenylmercury chloride, 2-chloromercuric-4-nitrophenol and other mercurials; carbamylation with cyanate at alkaline pH.
- Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphonyl halides.
- Tyrosine residues may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.
- Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodacetic acid derivatives of N-carbethoxylation with diethylpyrocarbonate.
- Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid-, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers or amino acids.
- Fragments or analogues of the peptides of the invention may be screened for their effectiveness by raising antibodies thereto in a suitable animal, as described herein, and screening the antibodies for their ability to neutralize the proteolytic activity of elastase, as described herein.
- the peptides of the invention may be coupled to a carrier protein to increase immunogenicity for antibody production.
- the peptides of the invention may be coupled to bovine serum albumin or keyhole limpet haemocyanin.
- fusion proteins containing a selected pepride such as peptide 15 or peptide 42
- a selected pepride such as peptide 15 or peptide 42
- Fusion proteins are commonly used as a source of antigen for producing antibodies.
- Two widely used expression systems for E. coli are lacZ fusions using the pUR series of vectors and trpE fusions using the pATH vectors.
- the peptides can then be purified, coupled to a carrier protein if desired, and mixed with Freund's adjuvant (to help stimulate the antigenic response of the animal) and injected into rabbits or other appropriate laboratory animals.
- the rabbits or other laboratory animals are bled and ther serum isolated.
- the serum can be used directly or the polyclonal antibodies purified prior to use by various methods including affinity chromatography.
- monoclonal antibodies may also be produced using the peptides of the invention.
- a selected peptide, coupled to a carrier protein if desired, is injected in Freund's adjuvant into mice. After being injected three times over a three week period, the mice spleens are removed and resuspended in phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- the spleen cells serve as a source of lymphocytes, some of which are producing antibody of the appropriate specificity.
- These are then fused with a permanently growing myeloma partner cell, and the products of the fusion are plated into a number of tissue culture wells in the presence of a selective agent such as HAT.
- the wells are then screened by ELISA to identify those containing cells making binding antibody. These are then plated and after a period of growth, these wells are again screened to identify antibody-producing cells. Several cloning procedures are carried out until over 90% of the wells contain single clones which are positive for antibody production. From this procedure a stable line of clones which produce the antibody is established.
- the monoclonal antibody can then be purified by affinity chromatography using Protein A Sepharose, ion-exchange chromatography, as well as variations and combinations of these techniques. Truncated versions of monoclonal antibodies may also be produced by recombinant techniques in which plasmids are generated which express the desired monoclonal antibody fragment in a suitable host.
- Antibodies to the peptides of the invention may be administered to a subject in acute situations to provide passive immunization.
- acute infection by a zinc metalloprotease-secreting pathogen in cancer patients or burn patients may be treated by passive immunization.
- Antibodies to the peptides of the invention are also useful for identification of microorganism strains, enabling the identification of bacterial strains which secrete metalloproteases.
- the peptides of the invention including peptides 15 and 42 and analogues and fragments thereof are also useful as antigens in immunoassays including enzyme-linked immunosorbent assays (ELISA), radioimmunoassays (RIA) and other non-enzyme linked antibody binding assays or procedures known in the art for the detection and assay of these peptides.
- immunoassays including enzyme-linked immunosorbent assays (ELISA), radioimmunoassays (RIA) and other non-enzyme linked antibody binding assays or procedures known in the art for the detection and assay of these peptides.
- Elastase and alkaline protease prepared from P. aeruginosa, were purchased from Nagase Biochemicals Inc. (Osaka, Japan).
- V. cholerae HA/protease was provided by Dr. R. A. Finkelstein (University of Missouri-Columbia School of Medicine, Columbia, Miss.).
- Thermolysin from B. thermoproteolyticus and the Serratia metalloprotease (SMP) from S. marcescens were purchased from Sigma Chemical Co. St. Louis, Mo. PSCP was purified as previously described (36).
- MAbs (36-6-6, 36-6-8, 36-1-5, 36-5-15, and 36-9-19) to PSCP were prepared as previously described in Reference 7 which is incorporated herein by reference. MAbs were purified using the Pierce IgM purification kit as recommended by the manufacturer.
- Elastase was digested with N-chlorosuccinimide (NCS; Aldrich) as previously described (37). Elastase (0.1 mg) was mixed with 0.15 g urea, 150 ⁇ l acetic acid and 50 ⁇ l 0.11 M NCS for a final concentration of 0.012 M NCS and digested for 30 min at room temperature. Reactions were stopped by the addition of 20% cold trichloroacetic acid. Samples were precipitated at ⁇ 20° C. for at least one hour and centrifuged at 10,000 ⁇ g for 30 min at 4° C. The resultant pellets were washed two times with ethanol:ether (1:1) and dried under vacuum. The dried pellets were resuspended in 1 ⁇ sample buffer and separated by tricine gel (16%) electrophoresis (38).
- NCS N-chlorosuccinimide
- SDS-PAGE was performed on 12.5k polyacrylamide gels by the method of Laemmli (39). Gels were either stained with Coomassie brilliant blue R-250 (Sigma) (0.25% Coomassie, 25% methanol, and 10% acetic acid) or electrophorectically blotted by the method of Towbin et al. (9). Blots were reacted with antibodies as previously described (7).
- aeruginosa ferripyochelin binding protein(40) did not react with any of the peptides.
- the MAb was stripped from the peptide pin by sonication in 0.1 M phosphate buffer, 1% SDS (w/v), 0.1% 2-mercaptoethanol (v/v) for 10 min followed by washing two times in dH 2 O at 60° C. for 30 sec. Peptide pins were then washed for 30 min in dH 2 O initially at 60° C., immersed in boiling methanol for at least 15 sec and air dried. Removal of the MAb was confirmed by testing the peptide pins with conjugate as described by the manufacturer.
- Rabbits immunized with peptide 42-BSA were boosted with intramuscular injections of peptide in incomplete Freund's three times at bi-weekly intervals. Rabbits immunized with peptide 15-BSA were given two additional boosts as test bleeds indicated lower titres.
- protease was preincubated with 10 mM Tris-HCl, pH 8.0, pre-immune rabbit serum, anti-peptide 15 serum or anti-peptide 42 serum at a dilution of 1:500 for 1 hour at 37° C.
- 10 mM Tris-HCl, pH 8.0 pre-immune rabbit serum, anti-peptide 15 serum or anti-peptide 42 serum at a dilution of 1:500 for 1 hour at 37° C.
- One ml was transferred to a microfuge tube containing 20 mg hide powder azure (Sigma) and 0.5 ml 10 mM Tris-HCl, pH 8.0.
- the samples were incubated for 2 h at 37° C. with shaking, centrifuged and the A 595 was measured. Assays were conducted in triplicate (7).
- an ELISA was performed. Immulon 4 96-well microtiter plates (Dynatech) were coated with 100 ⁇ l of each protease (1 ⁇ g/ml) in carbonate coating buffer (pH 9.6) for 2 h at 37° C. The plates were washed with buffer A (phosphate-buffered saline, pH 7.4, 0.05% (w/v) BSA) and blocked for 2 hr at 37° C. by the addition of 250 ⁇ l/well PBS, 5k BSA.
- buffer A phosphate-buffered saline, pH 7.4, 0.05% (w/v) BSA
- NCS N-chlorosuccinimide
- MAb 36-6-8 was found to recognize fragments of 26.5, 21.5, 19, 16.5 and 14 kDa on immunoblots (FIG. 3B). None of the fragments smaller than 14 kDa reacted with the MAb. MAb 36-6-6 was found to recognize the same fragments (data not shown). This pattern of recognition suggests that these MAbs recognize the 13.9 kDa NCS fragment of elastase as well as larger partially digested fragments which contain the 13.9 kDa fragment and one or more of the adjacent fragments. Complete digestion was not sought since higher NCS to elastase molar ratios can lead to oxidation and cleavage of methionine and cysteine residues.
- Numbering of the amino acids is from the elastase precursor. Peptides with sequences overlapping these peptides were also recognized to a lesser degree. Two control peptide pins were provided with the kit and these peptides responded as expected with the control antibody provided (see FIG. 1).
- Polyclonal antibodies to peptides 15 and 42 were obtained by immunizing rabbits with peptide 15 or 42 conjugated to BSA. Using peptides 15 and 42 conjugated to KLH as the coating antigen in ELISAs, peptide 15 and peptide 42 antisera had titres greater than 1:12,000 (Table 2). Both peptide 15 and peptide 42 antisera recognized intact elastase on immunoblots (FIGS. 4A and 4B) or ELISA (FIGS. 5A and 5B).
- MAbs 36-6-6 and 36-6-8 were previously reported to react with other bacterial metalloproteases, including thermolysin, P. aeruginosa alkaline protease, V. cholerae HA/protease, B. cepacia 40 kDa protease, and S. marcescens SMP (7,29). To determine if this crossreactivity was due to a recognition of conserved sequences corresponding to either peptide 15 or 42, the ability of antiserum to peptide 15 and antiserum to peptide 42 to crossreact with these metalloproteases was examined on immunoblots (FIGS. 4A and 4B).
- Proteases were separated by SDS- (12.5%) PAGE, blotted onto immobilon membranes and reacted with either peptide 15 (FIG. 4A) or peptide 42 (FIG. 4B).
- Peptide 15 antiserum was diluted 1:1,000 for reactions with elastase and 1:100 for reactions with the other metalloproteases.
- Peptide 42 antiserum was diluted 1:20,000 for reactions with elastase and 1:1,000 for reactions with other metalloproteases.
- Antiserum to peptide 15 or peptide 42 reacted weakly with other bacterial metalloproteases even at 10-20 fold higher antibody concentrations than used for elastase.
- a 1:100 dilution of antiserum to peptide 15 reacted strongly with HA/protease (FIG. 4A, lane 3) and faintly with alkaline protease (FIG. 4A, lane 4).
- Antipeptide 15 serum did not react with SMP, thermolysin, PSCP or the B. cepacia 40 kDa protease on immunoblots.
- Antiserum to peptide 42 at a 1:1000 dilution reacted strongly with HA/protease (FIG.
- Antiserum to peptide 15 had a similar affinity for all the proteases examined, with the exception of PSCP, which appeared to be lower than the others (FIG. 5A). Therefore, for antiserum to peptide 15, there was not a correlation between the results obtained with immunoblots of proteins denatured on SDS-PAGE and non-denatured proteins examined by ELISA. Antiserum to peptide 42 had a greater affinity for elastase and HA/protease in this assay as the absorbance at 405 nm was generally 2-3 fold higher for these two proteases at most dilutions in the linear portion of the binding curve (FIG. 5B). To achieve an absorbance between 0.5 and 1.3 in this assay required about one log less antibody when the plates were coated with elastase or HA/protease than with the other enzymes.
- the MAbs used to identify the epitopes corresponding to peptides 15 and 42 have been shown to neutralize thermolysin type metalloproteases but not serralysin proteases (29).
- the antipeptide polyclonal sera were examined for their ability to neutralize the activity of these metalloproteases, as described above, to determine if one epitope was responsible for inducing the production of neutralizing antibodies.
- Both peptide 15 and peptide 42 antisera were able to reduce the proteolytic activity of P. aeruginosa elastase, B. cepacia PSCP, thermolysin and V. cholerae HA/protease to low levels.
- the antisera did not inhibit alkaline protease or Serratia metalloprotease activity (Table 3).
- Rats were infected intratracheally using the agar bead model of Cash et al. (41) with a wild type strain of P. aeruginosa (PAO). At three and seven days after infection, the lungs of five rats in each group with lavaged with BSA. An aliquot of lavage was used to determine the PMN differential count and the remainder frozen at ⁇ 70° C. On day seven, quantitative bacteriology (41) was performed on five rats from each group and quantitative pathology (42) on 5-7 rats from each group.
- P. aeruginosa PAO
- PMN differential count (PMNs/WBCs) in the BAL (bronchial alveolar lavage) was significantly reduced in rats immunized with either peptide 15 or peptide 42 on day 3 compared to non-immunized rats and significantly lower in rats immunized with peptide 42 on day 7 compared to non-immunized rats, as shown in Table 4.
- Quantitative bacteriology was performed on five animals in each group on day 7. The mean values were 2.0 ⁇ 10 6 cfu/ml for the controls, 5.7 ⁇ 10 5 and 1.3 ⁇ 10 6 for animals immunized with peptide 15 and 42, respectively. Although the mean numbers of PAO recovered from the lungs was not significantly different, 2/5 animals in each of the groups immunized with peptide-conjugates had completely cleared the bacteria. All of the control animals remained infected. Quantitative pathology was performed on haematoxylin and eosin stains of sagittal slices of the left lobe of formalin fixed lungs by the method of Dunnill (42).
- the degree of pathology observed in the immunized animals was 40-50% less than that of control animals as shown in Table 5.
- 3/7 rats immunized with peptide 42 had 3% or less pathology, and 1/5 rats immunized with peptide 15 had 8% pathology.
Abstract
The present invention provides immunogenic compositions comprising peptides derived from the amino acid sequence of P. aeruginosa elastase for protecting susceptible hosts against diseases caused by bacterial pathogens which secrete a zinc metalloprotease.
Description
- The present invention relates to the field of immunization against bacterial diseases. In particular, it relates to immunization against diseases caused by bacteria which secrete zinc metalloproteases and to therapeutic vaccines for treatment of such diseases.
- In the description which follows, references are made to certain literature citations which are listed at the end of the specification.
- Many, bacteria produce and secrete zinc metalloproteases. For example,Pseudomonas aeruginosa produces at least two zinc metalloproteases, elastase and alkaline protease. Elastase degrades several important biological substances including elastin, immunoglobulins, collagen, transferrin and complement components (1). Alkaline protease has been shown to degrade C1q and C3 proteins of serum complement (2) and gamma interferon (3). P. aeruginosa also secretes Las A protease, which has both elastolytic and staphylolytic activity and has some properties of a metalloprotease (4-6).
-
-
-
- The bacterial metalloproteases have been shown to contribute to the virulence of many pathogenic organisms (14) which cause serious health problems.
- For example, pulmonary dysfunction as a result of chronic airway infection is responsible for the vast majority of deaths in cystic fibrosis (CF) patients (15). Despite advances in microbial therapy, the treatment and prevention of infections due toP. aeruginosa and B. cepacia remains a clinical challenge (15). Although major efforts are underway to develop gene therapy as a treatment for CF patients, the practical applications of gene therapy and potential for success may not be determined for some time. Other avenues of infection control continue to be an important area for investigation.
-
-
- The majority of strains (90%) ofB. cepacia are protease positive (18). Proteases appear to be the major extracellular virulence factors produced by B. cepacia. McKevvit et al. (19) isolated a zinc metalloprotease, designated PSCP, which was produced by 90% of B. cepacia CF isolates. This protease was shown to degrade casein, gelatin, collagen, but not elastin and to cause bronchopneumonia when instilled intratracheally into rats (19).
- Besides having a direct role in tissue destruction and injury, bacterial proteases such as elastase can function to modulate the host immune system and assist the bacterium in evading host defences (20-22).
- Numerous studies since the late 1970's have analyzed the presence of serum antibodies to severalP. aeruginosa antigens in CF patients (23-27). These studies all conclude that CF patients make antibodies to a variety of P. aeruginosa antigens and that elevated titres generally correlate with severity of disease.
- Although CF patients produce high levels of antibodies toP. aeruginosa, several studies have indicated that these antibodies are not effective in clearance of the organism from the lungs.
- These studies indicate that there remains a need for therapeutic strategies to improve the production of effective antibodies to combat infections with organisms such asP. aeruginosa and B. cepacia.
- The inventors have identified two regions of theP. aeruginosa amino acid sequence, and within these regions, two epitopes, which are recognized by antibodies which neutralise the proteolytic activity of P. aeruginosa elastase and other thermolysin-like proteases.
- Many pathogenic organisms secrete zinc metalloproteases which are thermolysin-like and their virulence is related to secretion of these enzymes.
- Peptides corresponding to the two identified regions of amino acid sequence, and peptides comprising fragments of these sequences, provide immunogenic compositions which can be administered to a host to stimulate production of neutralising antibodies and protect the host against diseases caused by pathogens which secrete thermolysin-like metalloproteases.
- Antibodies raised against the peptides of the invention also recognise serralysin-like proteases and immunization with these peptides may also be used to provide protection against pathogens secreting serralysin-like proteases.
- In accordance with one embodiment, the invention provides a peptide comprising the amino acid sequence
- VSHGFTEQNSGLIYRGQSGGMNEAF
- or a fragment or analogue thereof.
- In accordance with a further embodiment, the invention provides a peptide comprising the amino acid sequence HGFTEQNSG.
- In accordance with a further embodiment, the invention provides a peptide comprising the amino sequence
- SGALRYMDQPSRDGRSIDM
- or a fragment or analogue thereof.
- In accordance with a further embodiment, the invention provides a peptide comprising the amino acid sequence RYMDQPSRD.
- In accordance with a further embodiment, the invention provides an immunogenic composition comprising at least one active component selected from the group consisting of:
- (a) a peptide comprising the amino acid sequence HGFTEQNSG;
- (b) a peptide comprising the amino acid sequence RYMDQPSRD;
- (c) a peptide comprising the amino acid sequence VSHGFTEQNSGLIYRGQSGGMNEAF;
- (d) a peptide comprising the amino acid sequence SGALRYMDQPSRDGRSIDM;
- (e) a fragment or analogue of a peptide of (a), (b), (c) or (d);
- (f) a purified and isolated nucleic acid molecule encoding a peptide of (a), (b), (c) or (d); and
- (g) a nucleotide sequence which hybridises under stringent conditions to any of the nucleic acid molecules of (f)
- and a pharmaceutically acceptable carrier, the at least one active component producing an immune response when administered to a host.
- In accordance with a further embodiment, the invention provides an antibody or antiserum specific for a peptide selected from the group consisting of
- (a) VSHGFTEQNSGLIYRGQSGGMNEAF;
- (b) SGALRYMDQPSRDGRSIDM;
- (c) HGFTEQNSG;
- (d) RYMDQPSRD; and
- (e) a fragment or analogue of a peptide of (a), (b), (c) or (d).
- In accordance with a further embodiment, the invention provides a method for protecting a susceptible host against a disease caused by a bacterial pathogen which secretes a zinc metalloprotease.
- In accordance with a further embodiment, the invention provides a purified isolated nucleic acid molecule encoding a peptide selected from the group consisting of
- (a) VSHGFTEQNSGLIYRGQSGGMNEAF;
- (b) SGALRYMDQPSRDGRSIDM;
- (c) HGFTEQNSG;
- (d) RYMDQPSRD; and
- (e) a fragment or analogue of a peptide of (a), (b), (c) or (d).
- In accordance with a further embodiment, the invention provides a method of producing a vaccine comprising administering an immunogenic composition comprising at least one active component selected from the group consisting of:
- (a) a peptide comprising the amino acid sequence HGFTEQNSG;
- (b) a peptide comprising the amino acid sequence RYMDQPSRD;
- (c) a peptide comprising the amino acid sequence VSHGFTEQNSGLIYRGQSGGMNEAF;
- (d) a peptide comprising the amino acid sequence SGALRYMDQPSRDGRSIDM;
- (e) a fragment or analogue of a peptide of (a), (b), (c) or (d);
- (f) a purified and isolated nucleic acid molecule encoding a peptide of (a), (b), (c) or (d); and
- (g) a nucleotide sequence which hybridises under stringent conditions to any of the nucleic acid molecules of (f)
- and a pharmaceutically acceptable carrier to a test host to determine an amount and a frequency of administration of the active component to confer protection against a disease caused by a bacterial pathogen which secretes a zinc metalloprotease, and formulating the active component in a form suitable for administration to a host to be treated in accordance with the determined amount and frequency of administration.
- Certain embodiments of the invention are described, reference being made to the accompanying drawings, wherein:
- FIGS. 1A and 1B illustrate epitope mapping of a 13.9 kDa NCS-elastase fragment by peptide scanning analysis, as shown by ELISA reactions of MAb 36-6-6 (FIG. 1A) and MAb 36-6-8 (FIG. 1B) with sixty overlapping 9-mer peptides, with a two amino acid offset, encompassing the 13.9 kDa NCS-elastase fragment. Positive control peptides are indicated by asterisks.
- FIG. 2 shows a sequence comparison ofP.
aeruginosa elastase peptide 15 andpeptide 42 with other metalloproteases. The regions of metalloproteases with the greatest identity topeptide 15 andpeptide 42 were identified using the Pc/Gene QG Search program (Intelligenetics). Identical residues are boxed. Conservative amino acid changes are underlined. - FIG. 3A shows an SDS-PAGE analysis of peptides resulting from the partial digestion ofP. aeruginosa elastase with NCS. Peptides are stained with Coomassie blue. Lane 1: elastase digested for 1 min with NCS; Lane 2: elastase digested for 60 min with NCS; Lane 3: elastase incubated in buffer without NCS for 60 min; Lane 4: molecular mass markers: 45.5, 29.6, 18.7, 15.5, 5.9, and 2.9 kDa.
- FIG. 3B shows an immunoblot analysis of NCS-elastase fragments probed with MAb 36-6-8, an antibody toB. cepacia 36 kDa protease. Lanes are the same as in FIG. 3A.
- FIG. 4A shows an immunoblot of antiserum to
peptide 15 binding to various bacterial metalloproteases: Lane 1, elastase;lane 2, molecular mass markers;lane 3, V. cholerae HA/protease; lane 4, P. aeruginosa alkaline protease;lane 5, SMP; lane 6, thermolysin; lane 7, B. cepacia PSCP; lane 8, B. cepacia 40 kDa protease. - FIG. 4B shows immunoblot of antiserum to
peptide 42 binding to bacterial metalloproteases as in FIG. 4A. - FIG. 5A shows a comparison of ELISA binding curves of
peptide 15 antibodies to the following proteases: - PSCP (▪)
-
- Thermolysin (▾)
- HA/protease ()
- 40 kDaB. cepacia protease (∘)
- Alkaline protease (□)
- SMP (Δ)
- FIG. 5B shows a comparison of ELISA binding curves of
peptide 42 antibodies to various proteases identified as in FIG. 5A. - The zinc-dependent metalloproteases have been classified into two groups on the basis of their structure and secretion mechanism (14). The thermolysin-like or elastase-like group includesB. thermoproteolyticus thermolysin, P. aeruginosa elastase, PSCP and V. cholerae HA/protease. The serralysin-like group includes P. aeruginosa alkaline protease and Serratia marcescens protease.
- The zinc metalloproteases share a unique amino acid motif HExxH (28).
- Monoclonal antibodies raised against PSCP have been described (7,29) which neutralize the proteolytic activity of PSCP,P. aeruginosa elastase, thermolysin, and V. cholerae HA/protease but not P. aeruginosa alkaline protease nor Serratia marcescens SMP. These antibodies were used to determine which epitopes on these proteases were recognized by these broadly crossreactive antibodies. A combination of N-chlorosuccinimide cleavage to generate peptides, followed by overlapping synthetic peptide scanning analysis, was used to map the neutralizing epitopes. The neutralizing epitopes were mapped on P. aeruginosa elastase.
- All antibodies examined reacted strongly with peptides from two stretches of theP. aeruginosa elastase amino acid sequence, amino acids 339VSHGFTEQNSGLIYRGQSGGMNEAF363 and 391SGALRYMDQPSRDGRSIDM409. Table 1 shows the overlapping 9 mer peptides within each of these stretches which reacted with the antibodies, namely
peptides 14 to 22 for amino acids 339 to 363 and peptides 40-45 for amino acids 391 to 409. FIG. 1 shows the epitope mapping results. - All of the antibodies reacted most strongly with peptide 15 (341HGFTEQNSG349) and peptide 42 (395RYMDQPSRD403).
-
Peptide 15 overlaps the 337HExxH341 active site found in elastase. Antibody binding to the amino acid sequence 341HGFTEQNSG349 would explain the ability of these antibodies to neutralize elastase. An identical sequence is found in V. cholerae HA/protease (FIG. 2). Three of nine residues match the thermolysin sequence in the region of the HExxH motif, which may be sufficient for antibody binding and neutralization. A better match is found, however, in the region spanning residues 227-235, with four of nine residues identical topeptide 15. This region spans the Histidine at residue 231, which acts as a proton donor at the active site. Antibody binding to this epitope may be the reason that thermolysin is inactivated. - Peptide 42 (395RYMDQPSRD403) is located between E361, which binds a zinc atom, and H420, which acts as a proton donor at the active site (8, 30). The binding of antibodies to this epitope could effectively inhibit proteolytic activity by directly blocking the active site cleft. A nearly identical sequence is present in V. cholerae HA/protease, with eight of nine residues identical (FIG. 2). There is less homology between elastase and thermolysin in this region. Two possible epitopes recognized by the antibodies are between residues 192-200 and residues 203-211 of elastase. Both epitopes match
peptide 42 with three of nine residues identical. Both sequences are located between the zinc binding site and the H231 which serves as the proton donor. - Antibodies to
peptide 15 orpeptide 42 do not neutralize alkaline protease. The sequence with the best homology topeptide 15 spans residues 224-232 of alkaline protease, with four identical and two conserved residues (FIG. 2). This epitope is downstream of the active site and therefore, antibody binding to this site may have no effect on enzyme activity. Five other possible matches were identified with three identical residues (data not shown). Similarly, the best sequence match topeptide 42 lies between residues 238-246 of alkaline protease with only three residues conserved. This epitope is also downstream of the active site. There is no homology in the active site region. - Similar results were observed with Serratia SMP, which is closely related to alkaline proteases. A sequence with five of nine conserved residues with
peptide 15 occurs betweenresidues peptide 42 are found spanning amino acids 249-253 and 261-269. Although the epitopes on alkaline protease or SMP which are recognized by either the MAbs or the specific antibodies topeptides - Monoclonal antibodies 36-6-6 and 36-6-8 to PSCP were previously shown to crossreact also withP. aeruginosa LasA, and Bacillus anthracis protective antigen (PA) and lethal factor (LF) (29). This crossreaction might be explained by sequence homology to
peptides peptide 15. There is one possible epitope in LF with five conserved residues. Two possible sites with four residues conserved and five with three residues conserved are present in PA. In terms ofpeptide 42, there is one possible epitope in LasA with four conserved amino acids, three possible epitopes in PA with three conserved amino acids, and seven potential epitopes in LF with three conserved residues. - The ability of the antibodies to PSCP to crossreact withLegionella pneumophila protease has not been examined. However,
peptide antipeptide 15 andantipeptide 42 antibodies, would also neutralize L. pneumophila protease. - Antibody to
peptide 15 andpeptide 42 reacted better with nondenatured proteases in the ELISA assay than with denatured proteins on Western blots. The ability of the antibodies to react with proteases on Western blots appeared to correlate with the degree of sequence homology between the elastase epitopes corresponding topeptide - All of the neutralizing antibodies isolated to PSCP, even though they were individual clones, reacted most strongly with
peptides - The various embodiments of the present invention enable many applications for treatment of and vaccination against pathogenic bacterial species which secrete zinc metalloproteases.
- For bacterial species whose virulence is related to secreted thermolysin-like proteges, stimulation of an antibody response to the peptides of the invention, as described further below, will provide neutralising antibodies which combat the destructive proteolytic activity of the secreted proteases.
- Such bacterial species include pathogens of humans and other mammals and also pathogens of other vertebrates such as fish; for example such species include strains ofP. aeruginosa, B. cepacia, Vibrio cholerae, V. anguillarum, V. vulnificus, Legionella pneumophila, Staphylococcus epidermidis, and S. aureus.
- For bacterial species which produce and secrete serralysin-like proteases, which may not be neutralized by antibodies stimulated by the peptides of the invention, a protective effect may nevertheless be achieved where these antibodies bind to protease molecules on the bacterial cell surface, leading to opsonic and phagocytic destruction of the bacteria. Such bacterial species include strains ofS. marcescens and Aeromonas hydrophila.
- For bacterial species which produce thermolysin-like proteases, which may be neutralized by antibodies stimulated by the peptides of the invention, an additional protective effect may be achieved where these antibodies bind to protease molecules on the bacterial cell surface, leading to opsonic and phagocytic destruction of the bacteria. Such bacterial species include strains ofP. aeruginosa, B. cepacia, Vibrio cholerae, V. anguillarum, V. vulnificus, Legionella pneumophila, Staphylococcus epidermidis, and S. aureus.
- For bacterial species which produce zinc metalloproteases which may not have yet been classified, antibodies stimulated by the peptides of the invention may provide neutralizing antibodies and/or opsonophagocytic activity leading to the destruction of the bacteria. Such bacterial species include strains ofBacillus anthracis, Clostridium tetani, C. botulinum, Streptococcus sanguis, S. faecalis, Pasteurella haemolytica, and Lysteria monocytogenes.
- 1. Vaccine Preparation and Use
- Immunogenic compositions, suitable to be used as vaccines, may be prepared from peptide VSHGFTEQNSGLIYRGQSGGMEAF, peptide SGALRYMDQPSRDGRSIDM and fragments and analogues thereof, as disclosed herein.
- Peptides of about nine consecutive amino acids selected from the sequences VSHGFTEQNSGLIYRGQSGGMNEAF and SGALRYMDQPSRDGRSIDM, or analogues of such peptides, are preferred.
- Peptides HGFTEQNSG and RYMDQPSRD are especially preferred. An immunogenic composition may also be prepared from a peptide mixture, such as a mixture of peptides HGFTEQNSG and RYMDQPSRD.
- The peptide to be used as immunogen is preferably conjugated to a carrier protein to improve its immunogenicity. Suitable carrier proteins for immunogens for human use include keyhole limpet haemocyanin, diphtheria toxoid, diphtheria toxin CRM197, tetanus toxoid,P. aeruginosa exotoxin A mutant form, cholera toxin B subunit, pertussis toxin subunits, measles virus F protein and Haemophilus PRP outer membrane protein.
- Such immunogenic compositions elicit an immune response in a treated subject which produces antibodies, including
anti-peptide 15 and/or anti-peptide 42 antibodies. If the treated subject is challenged by P. aeruginosa, B. cepacia, Vibrio cholerae or other bacteria that secrete a thermolysin-like metalloprotease, the antibodies elicited by the vaccination neutralise the zinc metalloprotease of the invading organism and resist tissue destruction by the organism. - Antibodies produced in a subject in response to vaccination with one of the peptides of the invention may also provide protection by means of bactericidal or opsonising properties. For example, bacteria which have on their cell surface proteases which bind to the produced antibodies may be destroyed by opsonising and phagocytosis or by bactericidal activity in the presence of complement.
- Administration of the immunogenic compositions of the invention to a subject may be done either as a therapeutic measure after the subject has become infected with a zinc metalloprotease-producing. pathogen, or may be done as a prophylactic measure in subjects susceptible to infection with such pathogens.
- For example, chronic infections occurring in CF, panbronchiolitis or bronchitis may be treated therapeutically. Subjects susceptible to infections, for example cancer patients or burn patients or military personnel, may receive prophylactic immunisation.
- Vaccines containing proteins or peptides are generally well known in the art, as exemplified by U.S. Pat. Nos. 4,601,903; 4,599,231; 4,599,230; and 4,596,792; all of which references are incorporated herein by reference. Immunogenic compositions including vaccines may be prepared as injectables, as liquid solutions or as emulsions.
Peptide 15 orpeptide 42 or analogues or fragments thereof may be mixed with pharmaceutically acceptable excipients which are compatible with the peptides, fragments or analogues. Such excipients may include water, saline, dextrose, glycerol, ethanol, and combinations thereof. - The immunogenic compositions and vaccines of the invention may further contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness of the vaccines.
- Immunogenic compositions and vaccines may be administered parenterally, or by injection subcutaneously or intramuscularly. Alternatively, the immunogenic compositions formed according to the present invention may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. The oral, nasal, vaginal, gastrointestinal, respiratory or other mucosal route of vaccine administration may be preferred to combat infections which take place at mucosal surfaces, for example in the respiratory, digestive or urogenital tracts. Nasal immunization has been shown to be efficacious in generating both respiratory tract mucosal immunity and systemic immunity. Inhalation of an aerosol formulation may also be used to combat lung or respiratory tract infections.
- Delivery systems for mucosal immunization include lipid vesicles, biodegradable microcapsules, attenuated bacteria, live viral vectors and bacterial toxins or subunits thereof. For examples, cholera toxin B subunit may be conjugated to an -antigen for improved mucosal immunization.
- Targeting molecules such as strain B12 and fragments of bacterial toxins, are described in WO92/17167 (Biotech Australia Pty. Ltd.), and targeting monoclonal antibodies are described in U.S. Pat. No. 5,194,254 (Barber et al.). Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, polyalkalene glycols or triglycerides. Oral formulations may include normally employed excipients such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate. Immunogenic compositions may take the form of solutions, aerosols, suspensions, tablets, pills, capsules, sustained release formulations or powders and may comprise 10-95% of
peptide 15 orpeptide 42 or an analogue or fragment of one of these peptides. - The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic. The quantity of vaccine to be administered depends on the subject to be treated, including, for example, the weight of the subject and the capacity of the subject's immune system to synthesise antibodies, and if needed, to produce a cell-mediated immune response. The dosage of the vaccine may also depend on the route of administration. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of micrograms of the peptides, analogues or fragments thereof. Suitable regimes for initial administration and booster doses of vaccine are also well known in the art. These include an initial administration followed by subsequent administrations.
- Nucleic acid molecules encoding the peptides of the present invention may also be used for immunization. For example, DNA in a plasmid vector may be administered directly, in saline, by injection, preferably by intramuscular injection, for genetic immunization. It is believed that the DNA is expressed in vivo to give the encoded peptide antigen which stimulates an immune response. DNA may also be administered by constructing a live vector such as Salmonella, BCG, adenovirus, poxvirus, vaccinia or poliovirus including the DNA. Some live vectors that have been used to carry heterologous antigens to the immune system are discussed in, for example, O'Hagan (31). Processes for the direct injection of DNA into subjects for genetic immunization are described in, for example, Ulmer et al., (32). Nucleic acid molecules encoding the peptides of the invention may be obtained, for example, by excising the relevant portions ofP. aeruginosa elastase DNA, clones of which are available from the group which obtained this sequence (8).
- Alternatively, a nucleic acid molecule encoding a peptide of the invention conjugated to a selected carrier protein may be used for immunization, as described above.
- The immunogenicity of antigens can be significantly improved if they are co-administered with adjuvants. Adjuvants may be employed which not only enhance but selectively modulate the type of immune response to the administered antigen; for example monophosphoryl lipid A (MPL) favours a TH1 type response, while QS21 (Cambridge Biotech) favours a cytotoxic T cell response.
- Adjuvants or immunostimulatory agents are known to improve host immune responses to vaccines. Intrinsic adjuvants, such as lipopolysaccharides, normally are the components of the killed or attenuated bacteria used as vaccines. Aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are adjuvants commonly used in human and veterinary vaccines.
- An adjuvant should be non-toxic, capable of stimulating a sustained immune response and compatible with the immunogenic composition employed as a vaccine.
- U.S. Pat. No. 4,855,283 granted to Ockhoff et al. on Aug. 8, 1989 which is incorporated herein by reference teaches glycolipid analogues, including N-glycosylamide, N-glycosylureas and N-glycosylcarbamates, each of which is substituted in the sugar residues by an amino acid, as immuno-modulators or adjuvants. Lockhoff et al. (33) reported that N-glycolipid displaying structural similarities to the naturally occurring glycolipids, such as glycosphingolipids and glycoclycerolipids, are capable of eliciting strong immune responses both to herpes simplex virus and to pseudorabies virus. Some glycolipids have been synthesised from long chain-alkylamines and fatty acids that are linked directly with the sugars through the anomeric carbon atom, to mimic the functions of the naturally occurring lipid residues.
- Lipidation of synthetic peptides has also been used to increase their immunogenicity. Thus, Wiesmuller (34), describes a peptide with a sequence homologous to a foot-and-mouth disease viral protein coupled to an adjuvant tripalmityl-s-glyceryl-cysteinylserylserine, being a synthetic analogue of the N-terminal part of the lipoprotein from Gram negative bacteria. Furthermore, Deres et al. (35), reported in vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine which comprised modified synthetic peptides derived from influenza virus nucleoprotein by linkage to a lipopeptide, N-palmityl-s-[2,3-bis(palmitylxy)-(2RD)-propyl[R]-cysteine (TPC).
- 2. Preparation of Peptides
- Peptides in accordance with the invention or fragments or analogues thereof, may be prepared by any suitable peptide synthetic method.
- Chemical synthesis may be employed, for example standard solid phase peptide synthetic techniques may be used. In standard solid phase peptide synthesis, peptides of varying length can be prepared using commercially available equipment. This equipment can be obtained from Applied Biosystems (Foster City, Calif.). The reaction conditions in peptide synthesis are optimized to prevent isomerization of stereochemical centres, to prevent side reactions and to obtain high yields. The peptides are synthesized using standard automated protocols, using t-butoxycarbonyl-alpha-amino acids, and following the manufacturer's instructions for blocking interfering groups, protecting the amino acid to be reacted, coupling, deprotecting and capping of unreacted residues. The solid support is generally based on a polystyrene resin, the resin acting both as a support for the growing peptide chain, and as a protective group for the carboxy terminus. Cleavage from the resin-yields the free carboxylic acid. Peptides are purified by HPLC techniques, for example on a preparative C18 reverse phase column, using acetonitrile gradients in 0.1% trifluoroacetic acid, followed by vacuum drying.
- Peptides may also be produced by recombinant synthesis. A DNA sequence encoding the desired peptide is prepared, for example by cloning the required fragment from the DNA sequence encoding elastase, and subcloning into an expression plasmid DNA. Suitable mammalian expression plasmids include pRC/CMV from Invitrogen Inc. The gene construct is expressed in a suitable cell line, such as a Cos or CHO cell line and the expressed peptide is extracted and purified by conventional methods. Suitable methods for recombinant synthesis of peptides are described in “Molecular Cloning” (Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory Press, 1989).
- Analogues of a peptide may be prepared by similar synthetic methods. The term “analogue” extends to any functional and/or chemical equivalent of
peptide 15 orpeptide 42 and includes peptides having one or more conservative amino acid substitutions, peptides incorporating unnatural amino acids and peptides having modified side chains. - Examples of side chain modifications contemplated by the present invention include modification of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH4; amidation with methylacetimidate; acetylation with acetic anhydride; carbamylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6, trinitrobenzene sulfonic acid (TNBS); alkylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5′-phosphate followed by reduction with NaBH4.
- The guanidino group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2, 3-butanedione, phenylglyoxal and glyoxal.
- The carboxyl group may be modified by carbodiimide activation via -acylisourea formation followed by subsequent derivatisation, for example, to a corresponding amide.
- Sulfhydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulfonic acid, phenylmercury chloride, 2-chloromercuric-4-nitrophenol and other mercurials; carbamylation with cyanate at alkaline pH.
- Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphonyl halides. Tyrosine residues may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.
- Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodacetic acid derivatives of N-carbethoxylation with diethylpyrocarbonate.
- Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid-, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers or amino acids.
- Examples of conservative amino acid substitutions are substitutions within the following five groups of amino acids:
Group 1: F Y W Group 2: V L I Group 3: H K R Group 4: M S T P A G Group 5: D E - Fragments or analogues of the peptides of the invention may be screened for their effectiveness by raising antibodies thereto in a suitable animal, as described herein, and screening the antibodies for their ability to neutralize the proteolytic activity of elastase, as described herein.
- 3. Antibodies
- The peptides of the invention may be coupled to a carrier protein to increase immunogenicity for antibody production. For example, the peptides of the invention may be coupled to bovine serum albumin or keyhole limpet haemocyanin.
- In order to prepare peptides for production of polyclonal antibodies, fusion proteins containing a selected pepride, such as
peptide 15 orpeptide 42, can be synthesized in bacteria by expression of corresponding DNA sequences in a suitable cloning vehicle. Fusion proteins are commonly used as a source of antigen for producing antibodies. Two widely used expression systems for E. coli are lacZ fusions using the pUR series of vectors and trpE fusions using the pATH vectors. The peptides can then be purified, coupled to a carrier protein if desired, and mixed with Freund's adjuvant (to help stimulate the antigenic response of the animal) and injected into rabbits or other appropriate laboratory animals. - Following booster injections at weekly intervals, the rabbits or other laboratory animals are bled and ther serum isolated. The serum can be used directly or the polyclonal antibodies purified prior to use by various methods including affinity chromatography.
- As will be understood by those skilled in the art, monoclonal antibodies may also be produced using the peptides of the invention. A selected peptide, coupled to a carrier protein if desired, is injected in Freund's adjuvant into mice. After being injected three times over a three week period, the mice spleens are removed and resuspended in phosphate buffered saline (PBS). The spleen cells serve as a source of lymphocytes, some of which are producing antibody of the appropriate specificity. These are then fused with a permanently growing myeloma partner cell, and the products of the fusion are plated into a number of tissue culture wells in the presence of a selective agent such as HAT. The wells are then screened by ELISA to identify those containing cells making binding antibody. These are then plated and after a period of growth, these wells are again screened to identify antibody-producing cells. Several cloning procedures are carried out until over 90% of the wells contain single clones which are positive for antibody production. From this procedure a stable line of clones which produce the antibody is established. The monoclonal antibody can then be purified by affinity chromatography using Protein A Sepharose, ion-exchange chromatography, as well as variations and combinations of these techniques. Truncated versions of monoclonal antibodies may also be produced by recombinant techniques in which plasmids are generated which express the desired monoclonal antibody fragment in a suitable host.
- Antibodies to the peptides of the invention may be administered to a subject in acute situations to provide passive immunization. For example, acute infection by a zinc metalloprotease-secreting pathogen in cancer patients or burn patients may be treated by passive immunization.
- Antibodies to the peptides of the invention, including antibodies to
peptides - 4. Assays
- The peptides of the invention, including
peptides - The examples are described for the purposes of illustration and are not intended to limit the scope of the invention.
- Methods of molecular genetics, protein and peptide biochemistry and immunology referred to but not explicitly described in this disclosure and examples are reported in the scientific literature and are well known to those skilled in the art.
- Materials and Methods
- Proteases.
- Elastase and alkaline protease, prepared fromP. aeruginosa, were purchased from Nagase Biochemicals Inc. (Osaka, Japan). V. cholerae HA/protease was provided by Dr. R. A. Finkelstein (University of Missouri-Columbia School of Medicine, Columbia, Miss.). Thermolysin from B. thermoproteolyticus and the Serratia metalloprotease (SMP) from S. marcescens were purchased from Sigma Chemical Co. St. Louis, Mo. PSCP was purified as previously described (36).
- Monoclonal Antibodies and Purification.
- MAbs (36-6-6, 36-6-8, 36-1-5, 36-5-15, and 36-9-19) to PSCP were prepared as previously described in Reference 7 which is incorporated herein by reference. MAbs were purified using the Pierce IgM purification kit as recommended by the manufacturer.
- NCS Digestion of Elastase.
- Elastase was digested with N-chlorosuccinimide (NCS; Aldrich) as previously described (37). Elastase (0.1 mg) was mixed with 0.15 g urea, 150 μl acetic acid and 50 μl 0.11 M NCS for a final concentration of 0.012 M NCS and digested for 30 min at room temperature. Reactions were stopped by the addition of 20% cold trichloroacetic acid. Samples were precipitated at −20° C. for at least one hour and centrifuged at 10,000× g for 30 min at 4° C. The resultant pellets were washed two times with ethanol:ether (1:1) and dried under vacuum. The dried pellets were resuspended in 1× sample buffer and separated by tricine gel (16%) electrophoresis (38).
- SDS-PAGE and Immunoblotting.
- SDS-PAGE was performed on 12.5k polyacrylamide gels by the method of Laemmli (39). Gels were either stained with Coomassie brilliant blue R-250 (Sigma) (0.25% Coomassie, 25% methanol, and 10% acetic acid) or electrophorectically blotted by the method of Towbin et al. (9). Blots were reacted with antibodies as previously described (7).
- Epitope Mapping.
- Sixty 9-mer overlapping peptides, with a two amino acid offset, encompassing the 13.9 kDa NCS-elastase fragment, were synthesized on pins using an epitope scanning kit, as suggested by the manufacturer (Chiron Mimotopes, Australia). Two additional control peptides were synthesized. PLRQ was a positive control for the antibody (Ab) provided by the manufacturer, and GLAQ was a negative control. Two additional control peptide pins were provided with the kit. Peptides were tested for recognition by the five purified MAbs to PSCP (1:100 dilution) by ELISA as suggested by the manufacturer. An unrelated control MAb (#6), toP. aeruginosa ferripyochelin binding protein(40), did not react with any of the peptides. After each test, the MAb was stripped from the peptide pin by sonication in 0.1 M phosphate buffer, 1% SDS (w/v), 0.1% 2-mercaptoethanol (v/v) for 10 min followed by washing two times in dH2O at 60° C. for 30 sec. Peptide pins were then washed for 30 min in dH2O initially at 60° C., immersed in boiling methanol for at least 15 sec and air dried. Removal of the MAb was confirmed by testing the peptide pins with conjugate as described by the manufacturer.
- Polyclonal antibody production. Peptides HGFTEQNSG (peptide 15) and LRYMDQPSRD (peptide 42) and the same peptides conjugated to bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH) were synthesized by the Alberta Peptide Institute, Edmonton, Canada. Conjugates were prepared for immunization as suggested by the manufacturer. The BSA conjugates were prepared in complete Freund's adjuvant and 0.5 ml containing 0.1 mg of either peptide 15-BSA or peptide 42-BSA was injected in each thigh of two New Zealand white rabbits. Rabbits immunized with peptide 42-BSA were boosted with intramuscular injections of peptide in incomplete Freund's three times at bi-weekly intervals. Rabbits immunized with peptide 15-BSA were given two additional boosts as test bleeds indicated lower titres.
- ELISA.
- To determine the antibody titres, 96-well plates were coated with either the BSA-peptide conjugate or the KLH-peptide conjugate (1 μl/well). Use of the heterologous conjugate was used to indicate whether the antibodies present were due to peptide antibodies or BSA antibodies or both. The assay was performed as previously described (7).
- Neutralization Assays.
- For neutralization assays, protease was preincubated with 10 mM Tris-HCl, pH 8.0, pre-immune rabbit serum, anti-peptide 15 serum or anti-peptide 42 serum at a dilution of 1:500 for 1 hour at 37° C. One ml was transferred to a microfuge tube containing 20 mg hide powder azure (Sigma) and 0.5
ml 10 mM Tris-HCl, pH 8.0. The samples were incubated for 2 h at 37° C. with shaking, centrifuged and the A595 was measured. Assays were conducted in triplicate (7). - ELISA to Measure Antibody Affinity.
- To compare the affinity of antibodies to
peptide 15 andpeptide 42 for the various proteases employed, an ELISA was performed. Immulon 4 96-well microtiter plates (Dynatech) were coated with 100 μl of each protease (1 μg/ml) in carbonate coating buffer (pH 9.6) for 2 h at 37° C. The plates were washed with buffer A (phosphate-buffered saline, pH 7.4, 0.05% (w/v) BSA) and blocked for 2 hr at 37° C. by the addition of 250 μl/well PBS, 5k BSA. Following two washes with buffer A, serial two-fold dilutions, starting at 1:100 of anti-peptide 15 oranti-peptide 42 rabbit serum in buffer A (100 μl/well), were applied to the wells. All assays were performed in duplicate and included negative controls in which no antibody was present. After a two hr incubation at 37° C., the plates were washed five times with buffer A. Protein A-peroxidase conjugate (100 μl, 1:2000; Sigma) was added to each well and incubated at 37° C. for 2 hr. Wells were washed five times with buffer A and aspirated thoroughly. ABTS substrate (100 μl/well, BioRad) was applied to each well and after agitation at room temperature for 15 min, the A405 was determined using an EL340 BioKinetics Reader (Bio-Tek Instruments). - In order to determine which epitopes are recognized by elastase neutralizing MAbs, overlapping peptides were synthesized based on the sequence ofP. aeruginosa elastase. Polyclonal antisera were raised against the peptides corresponding to the mapped epitopes to determine whether the anti-peptide antibodies (Abs) could neutralize various metalloproteases.
- Recognition of NCS-elastase Fragments by MAbs.
- Chemical cleavage ofP. aeruginosa elastase followed by immunoblot analysis was used to localize the epitope recognized by the neutralizing MAbs. The chemical N-chlorosuccinimide (NCS), which cleaves after Trp residues, was used to digest elastase. Complete digestion of elastase with NCS would result in fragments of 9.9, 3.0, 13.9, 2.2 and 4.3 kDa (in order from the N-terminus). Incomplete digestion of elastase was obtained, resulting in fragments of 26.5, 21.5, 19, 16.5, 14, 10 and 4 kDa (FIG. 3A). MAb 36-6-8 was found to recognize fragments of 26.5, 21.5, 19, 16.5 and 14 kDa on immunoblots (FIG. 3B). None of the fragments smaller than 14 kDa reacted with the MAb. MAb 36-6-6 was found to recognize the same fragments (data not shown). This pattern of recognition suggests that these MAbs recognize the 13.9 kDa NCS fragment of elastase as well as larger partially digested fragments which contain the 13.9 kDa fragment and one or more of the adjacent fragments. Complete digestion was not sought since higher NCS to elastase molar ratios can lead to oxidation and cleavage of methionine and cysteine residues.
- Epitope Mapping of the 13.9 kDa NCS-elastase Fragment.
- Sixty overlapping 9-mer peptides, with a two amino acid offset, were synthesized spanning the 13.9 kDa NCS-elastase fragment. The first peptide was DGTAMLFGD and the last was YLLANSPGW. In addition, two control peptides were synthesized, PLRQ (positive) and GLAQ (negative). Essentially the same results were found with all five antibodies. The results with two representative antibodies, Mabs 36-6-6 and 36-6-8, are shown in FIG. 1. MAbs 36-6-6 and 36-6-8 bound most strongly to peptides 15 (341HGFTEQNSG349) and 42 (395RYNDQPSRD403). Numbering of the amino acids is from the elastase precursor. Peptides with sequences overlapping these peptides were also recognized to a lesser degree. Two control peptide pins were provided with the kit and these peptides responded as expected with the control antibody provided (see FIG. 1).
- Characterization of Polyclonal Antibodies to
Peptides - Polyclonal antibodies to
peptides peptide peptides peptide 15 andpeptide 42 antisera had titres greater than 1:12,000 (Table 2). Bothpeptide 15 andpeptide 42 antisera recognized intact elastase on immunoblots (FIGS. 4A and 4B) or ELISA (FIGS. 5A and 5B). - MAbs 36-6-6 and 36-6-8 were previously reported to react with other bacterial metalloproteases, including thermolysin,P. aeruginosa alkaline protease, V. cholerae HA/protease, B. cepacia 40 kDa protease, and S. marcescens SMP (7,29). To determine if this crossreactivity was due to a recognition of conserved sequences corresponding to either
peptide peptide 15 and antiserum topeptide 42 to crossreact with these metalloproteases was examined on immunoblots (FIGS. 4A and 4B). - Proteases were separated by SDS- (12.5%) PAGE, blotted onto immobilon membranes and reacted with either peptide 15 (FIG. 4A) or peptide 42 (FIG. 4B).
Peptide 15 antiserum was diluted 1:1,000 for reactions with elastase and 1:100 for reactions with the other metalloproteases.Peptide 42 antiserum was diluted 1:20,000 for reactions with elastase and 1:1,000 for reactions with other metalloproteases. - Antiserum to
peptide 15 orpeptide 42 reacted weakly with other bacterial metalloproteases even at 10-20 fold higher antibody concentrations than used for elastase. A 1:100 dilution of antiserum topeptide 15 reacted strongly with HA/protease (FIG. 4A, lane 3) and faintly with alkaline protease (FIG. 4A, lane 4).Antipeptide 15 serum did not react with SMP, thermolysin, PSCP or the B. cepacia 40 kDa protease on immunoblots. Antiserum topeptide 42 at a 1:1000 dilution reacted strongly with HA/protease (FIG. 4B, lane 3) and more weakly with thermolysin, PSCP, and B. cepacia 40 kDa protease (FIG. 4B, lanes 6,7, and 8, respectively).Antipeptide 42 serum did not recognize alkaline protease nor SMP on these blots. Therefore, both antipeptide sera were capable of recognizing other metalloproteases, but they differed with respect to their reactions with these proteases on immunoblots. - Previously, the affinity of MAb 36-6-8 for various metalloproteases was estimated by comparing the dose response curves of this MAb, using the same concentration of each protease, in an ELISA (29). To determine if the antipeptide antibodies could react with non-denatured forms of the metalloproteases examined above, a similar assay was performed (FIG. 5). Microtiter plates were coated with 0.1 μg/well protease, reacted with serial two-fold dilutions of anti-peptide sera starting at a 1:100 dilution and processed as described above. The antisera to
peptide 15 andpeptide 42 both reacted in the ELISA with all the proteases examined. Antiserum topeptide 15 had a similar affinity for all the proteases examined, with the exception of PSCP, which appeared to be lower than the others (FIG. 5A). Therefore, for antiserum topeptide 15, there Was not a correlation between the results obtained with immunoblots of proteins denatured on SDS-PAGE and non-denatured proteins examined by ELISA. Antiserum topeptide 42 had a greater affinity for elastase and HA/protease in this assay as the absorbance at 405 nm was generally 2-3 fold higher for these two proteases at most dilutions in the linear portion of the binding curve (FIG. 5B). To achieve an absorbance between 0.5 and 1.3 in this assay required about one log less antibody when the plates were coated with elastase or HA/protease than with the other enzymes. - Neutralization of Protease Activity
- The MAbs used to identify the epitopes corresponding to
peptides peptide 15 andpeptide 42 antisera were able to reduce the proteolytic activity of P. aeruginosa elastase, B. cepacia PSCP, thermolysin and V. cholerae HA/protease to low levels. The antisera did not inhibit alkaline protease or Serratia metalloprotease activity (Table 3). - Seventy eight seven-week old Sprague-Dawley rats were immunized subcutaneously with 50 μg of
peptide 15 orpeptide 42 conjugated to KLH (15-KLH or 42-KLH) and boosted three times at two week intervals with 25 μg of the appropriate conjugate. Control rats were injected with saline plus adjuvant. Three rats from each group were bled six days after each boost and the presence of anti-peptide antibodies determined. After the second boost, 2/3 of each of the immunized groups had anti-peptide antibodies. After boost three, 3/3 rats in each of the immunized groups had anti-peptide antibodies. The mean antibody titres topeptides - Rats were infected intratracheally using the agar bead model of Cash et al. (41) with a wild type strain ofP. aeruginosa (PAO). At three and seven days after infection, the lungs of five rats in each group with lavaged with BSA. An aliquot of lavage was used to determine the PMN differential count and the remainder frozen at −70° C. On day seven, quantitative bacteriology (41) was performed on five rats from each group and quantitative pathology (42) on 5-7 rats from each group.
- The PMN differential count (PMNs/WBCs) in the BAL (bronchial alveolar lavage) was significantly reduced in rats immunized with either
peptide 15 orpeptide 42 onday 3 compared to non-immunized rats and significantly lower in rats immunized withpeptide 42 on day 7 compared to non-immunized rats, as shown in Table 4. - These data show that immunization with either peptide reduces the inflammatory response in the lungs. Even though the serum antibody titres were lower to
peptide 42 than 15,peptide 42 immunization was at least as effective in reducing the PMN infiltration in the lung. - Quantitative bacteriology was performed on five animals in each group on day 7. The mean values were 2.0×106 cfu/ml for the controls, 5.7×105 and 1.3×106 for animals immunized with
peptide - The degree of pathology observed in the immunized animals was 40-50% less than that of control animals as shown in Table 5. 3/7 rats immunized with
peptide 42 had 3% or less pathology, and 1/5 rats immunized withpeptide 15 had 8% pathology. The lowest amount of infiltration in the control group, however, was 18% and 4/6 control rats had >44% pathology. - Numerous studies have reported that CF patients produce high levels of antibodies but most often these are not functional antibodies. Studies were carried out to determine if CF patients produce antibodies to the peptides identified as neutralizing epitopes. Sera from 84 CF patients taken at their most recent clinic visit were examined by ELISA to determine their antibody titre toP. aeruginosa elastase, peptide 15- or 42-BSA conjugate or peptide 15- or 42-KLH conjugate. Pooled normal human serum was used as a control. Titres were considered positive if the A450 was at least twice the backgound of the normal human serum pool. 62 of the 84 sera (74%) were positive for anti-elastase. antibodies. Four patients (5%) had antibodies detectable by ELISA to both
peptides peptide - The present invention is not limited to the features of the embodiments described herein, but includes all variations and modifications within the scope of the claims.
- 1.Wretlind, B., and O. R. PavloVskis (1983),Rev. Infect. Dis. 5(Suppl.): 998-1004.
- 2. Hong, Y. Q., and Ghebrehiwet, B. (1992),Clin. Immunol. Immunopathol. 62:133-138.
- 3. Horvat, R. T. and M. J. Parmely (1988),Infect. Immun. 56:2925-2932.
- 4. Kessler, E., M. Safrin, J. C. Olson and D. E. Ohman (1993),J. Biol. Chem. 268:7503-7508.
- 5. Olson, J. C. and D. E. Ohman (1992),J. Bacteriol., 174:4140-4147.
- 6. Toder, D. S., S. J. Ferrell, J. L. Nezezon, L. Rust, and B. H. Iglewski (1994),Infect. Immun. 62:1320-1327.
- 7. Kooi, C., A. Cox, P. Darling, and P. A. Sokol (1994),Infect. Immun., 62:2811-2817.
- 8.Bever, R. A., and B. H. Iglewski (1988),J. Bacteriol., 170:4309-4314.
- 9. Towbin, H., T. Staehelin, and J. Gordon (1979),Proc. Natl. Acad. Sci. USA, 76:4350-4354.
- 10. Booth, B. A., M. Boesman-Finkelstein, and R. Finkelstein, (1983),Infect. Immun., 42:639-644.
- 11. Finkelstein, R. A., M. Boseman-Finkelstein, and P. Holt, (1983),Proc. Natl. Acad. Sci. USA, 80:1092-1095.
- 12.Hase, C. C., and R. A. Finkelstein, (1990),Infect. Immun., 58:5011-4015.
- 13. Hase, C. C., and R. A. Finkelstein, (1991),J. Bacteriol., 173:3311-3317.
- 14. Hase, C. C., and R. A. Finkelstein, (1993),Microbiol. Reviews, 57:823-837.
- 15. Gilligan P. H. (1991),Clin. Microbiol. Rev., 4:35-51.
- 16. Pegues, D. A., L. A. Carson, R. L. Anderson, M. J. Norgard, T. A. Argent, W. R. Jarvis, and C. H. Woernle, (1993),Clin. Infect. Dis., 16:407-11.
- 17. Taylor, R. F. H., H. Gaya and M. E. Hodson, (1993),Resp. Medicine, 87:187-192.
- 18. McKevitt, A. L. and D. E. Woods (1984),J. Clin. Micro., 19:291-293.
- 19. McKevitt, A. L., S. Bajaksouzian, J. D. Klinger, and D. E. Woods, (1989),Infect. Immun., 57:771-778.
- 20. Fick, R. B. Jr., R. S. Baltimore, S. U. Squier, and H. R. Reynolds, (1985),J. Inf. Dis., 151:589-598.
- 21.Bainbridge, T. and R. B. Fick, Jr., (1989),J. Clin. Lab. Med., 114:728-733.
- 22. Horvat, R. T., M. Clabaugh, C. Duval-Jobe, and M. J. Parmely, (1989),Infect. Immun., 57:1668-1674.
- 23. Klinger, J. D., D. C. Straus, C. B. Hilton, and J. A. Bass, (1978),J. Inf. Dis., 138:49-58.
- 24. Jagger, K. S., D. L. Robinson, M. N. Franz, and R. L. Warren (1982),J. Clin. Micro., 15:1054-1058.
- 25. Doring, G., H. J. Obernesser, K. Botzenhart, B. Flehmig, N. Hoiby, and A. Hofmann, (1983),J. Inf. Dis., 147:744-750.
- 26. Hollsing, A. E., M. Granstrom, M. L. Vasil, B. Wretlind, and B. Strandvik, (1987),J. Clin, Mocrobiol., 25:1868:1874.
- 27. Granstrom, M., A. Ericsson, B. Strandvik, B. Wretlind, O. R. Pavloskis, R. Berka, and M. L. Vasil, (1984),Acta. Paediatr. Scand., 73:772-777.
- 28. Jongeneel, C. V., J. Bouvier, and A. Bairoich, (1989),FEBS Lett., 242:211-214.
- 29. Kooi, C., and P. A. Sokol, (1996),J. Med. Microbiol., In Press.
- 30. Thayer, M. M., K. M. Flaherty and D. B. McKay, (1991),J. Biol. Chem., 266:2864-2871.
- 31. O'Hagan (1992),Clin. Pharmacokinet, 22:1.
- 32. Ulmer et al., 91993),Curr. Opinion Invest. Drugs, 2(9):983.
- 33. Lockhoff et al., (1991),Chem. Int. Ed. Engl., 30:1611.
- 34. Wiesmuller et al., (1989),Vaccine, 8:29.
- 35. Deres et al., (1989),Nature, 342:651.
- 36. McKevitt, A. I., S. Bajaksouzian, J. D. Klinger, and D. E. Woods (1989),Infect. Immun., 57:771-778.
- 37. Lischwe, M. A. and M. T. Sung, (1977),J. Biol. Chem., 252:4976-4980.
- 38. Schagger, H. and G. Von Jagow, (1987),Anal. Biochem., 166:368-379.
- 39. Laemmli, V. K., (1970),Nature (London), 277:680-685.
- 40. Sokol, P. A., and D. E. Woods (1986),Infect. Immun., 53:621-627.
- 41. Cash, H. A., D. E. Woods, B. McCullough, W. G. Johanson, Jr. and J. A. Bass, (1979),Am. Rev. Resp. Dis., 119:453-459.
- 42. Dunnill, M. S. (1962),Thorax, 17:320-328.
TABLE 1 P. aeruginosa elastase peptides reacting with MAbs 14 VSHGFTEQN 15 HGFTEQNSG 16 FTEQNSGLI 17 EQNSGLIYR 18 NSGLIYRGQ 19 GLIYRGQSG 20 IYRGQSGGM 21 RGQSGGMNE 22 QSGGMNEAF 40 SGALRYMDQ 41 ALRYMDQPS 42 RYMQPSRD 43 MDQPSRDGR 44 QPSRDGRSI 45 SRDGRSIDM -
TABLE 2 ELISA titers of sera raised against peptide 15- or 42- BSA conjugates, tested against peptide 15- or 42-KLH conjugates as antigen Antisera to Peptide 15-KLH to Peptide 42-KLH anti-peptide 15- 1:12,800 1:6400 BSA anti-peptide 42- 1:3200 1:51,200 BSA -
TABLE 3 Comparison of the ability of antiserum to peptide 15 andpeptide 42 toneutralize proteolytic activity Proteolytic Activitya Peptide 15 Peptide 42Control Protease Antiserum Antiserum Rabbit Serum Thermolysin 2 ± 3b 3 ± 1b 85 ± 13 V. cholerae HA/ protease 12 ± 17b 10 ± 13b 121 ± 7 P. aeruginosa Elastase 2 ± 1b 15 ± 9b 88 ± 1 B. cepacia PSCP 4 ± 0.1b 4 ± 3b 135 ± 13 P. aeruginosa Alkaline Protease 88 ± 2 100 ± 5 103 ± 3 Serratia metalloprotease 89 ± 6 105 ± 1 110 ± 16 -
TABLE 4 DAY 3DAY 7 TREATMENT % PMNa p valueb % PMN p valueb control 48.6 ± 11.6 — 17.0 ± 3.7 — peptide 16.4 ± 11.9 .001* 14.2 ± 12.0 .33 15 peptide 27.8 ± 13.7 0.32* 6.0 ± 5.3 .01* 42 -
TABLE 5 % Pathology % Pathology Treatment n (mean ± sd) Range Control 6 44.2 ± 22.1 18-78 Peptide 155 25.0 ± 10.0 8-33 Peptide 427 22.3 ± 20.1 3-46 -
-
1 29 25 amino acids amino acid single linear peptide 1 Val Ser His Gly Phe Thr Glu Gln Asn Ser Gly Leu Ile Tyr Arg Gly 1 5 10 15 Gln Ser Gly Gly Met Asn Glu Ala Phe 20 25 9 amino acids amino acid single linear peptide 2 Val Ser His Gly Phe Thr Glu Gln Asn 1 5 9 amino acids amino acid single linear peptide 3 His Gly Phe Thr Glu Gln Asn Ser Gly 1 5 9 amino acids amino acid single linear peptide 4 Phe Thr Glu Gln Asn Ser Gly Leu Ile 1 5 9 amino acids amino acid single linear peptide 5 Glu Gln Asn Ser Gly Leu Ile Tyr Arg 1 5 9 amino acids amino acid single linear peptide 6 Asn Ser Gly Leu Ile Tyr Arg Gly Gln 1 5 9 amino acids amino acid single linear peptide 7 Gly Leu Ile Tyr Arg Gly Gln Ser Gly 1 5 9 amino acids amino acid single linear peptide 8 Ile Tyr Arg Gly Gln Ser Gly Gly Met 1 5 9 amino acids amino acid single linear peptide 9 Arg Gly Gln Ser Gly Gly Met Asn Glu 1 5 9 amino acids amino acid single linear peptide 10 Gln Ser Gly Gly Met Asn Glu Ala Phe 1 5 19 amino acids amino acid single linear peptide 11 Ser Gly Ala Leu Arg Tyr Met Asp Gln Pro Ser Arg Asp Gly Arg Ser 1 5 10 15 Ile Asp Met 9 amino acids amino acid single linear peptide 12 Ser Gly Ala Leu Arg Tyr Met Asp Gln 1 5 9 amino acids amino acid single linear peptide 13 Ala Leu Arg Tyr Met Asp Gln Pro Ser 1 5 9 amino acids amino acid single linear peptide 14 Arg Tyr Met Asp Gln Pro Ser Arg Asp 1 5 9 amino acids amino acid single linear peptide 15 Met Asp Gln Pro Ser Arg Asp Gly Arg 1 5 9 amino acids amino acid single linear peptide 16 Gln Pro Ser Arg Asp Gly Arg Ser Ile 1 5 9 amino acids amino acid single linear peptide 17 Ser Arg Asp Gly Arg Ser Ile Asp Met 1 5 9 amino acids amino acid single linear peptide 18 Asp Gly Thr Ala Met Leu Phe Gly Asp 1 5 9 amino acids amino acid single linear peptide 19 Tyr Leu Leu Ala Asn Ser Pro Gly Trp 1 5 9 amino acids amino acid single linear peptide 20 Arg Tyr Phe Asp Gln Pro Ser Arg Asp 1 5 9 amino acids amino acid single linear peptide 21 His Ala Val Thr Asp Tyr Thr Ala Gly 1 5 9 amino acids amino acid single linear peptide 22 Arg Ser Met Ser Asp Pro Ala Lys Tyr 1 5 9 amino acids amino acid single linear peptide 23 Asn Gly Gly Val His Ile Asn Ser Gly 1 5 9 amino acids amino acid single linear peptide 24 Val Tyr Thr Pro Gly Ile Ser Gly Asp 1 5 9 amino acids amino acid single linear peptide 25 Ser Tyr Trp Glu Glu Gln Asn Thr Gly 1 5 9 amino acids amino acid single linear peptide 26 Ala Tyr Ser Ser Ala Pro Leu Leu Asp 1 5 9 amino acids amino acid single linear peptide 27 Ile Thr Phe Thr Glu Val Ala Ala Gly 1 5 9 amino acids amino acid single linear peptide 28 Leu Tyr Gly Ala Asn Pro Ser Thr Arg 1 5 9 amino acids amino acid single linear peptide 29 His Tyr Ala Ala Ala Pro Leu Leu Asp 1 5
Claims (24)
1. A peptide comprising the amino acid sequence
VSHGFTEQNSGLIYRGQSGGMNEAF (Sequence ID No:1)
or a fragment or analogue thereof.
2. The peptide of claim 1 wherein the peptide has an amino acid sequence comprising about nine consecutive amino acids from the amino acid sequence VSHGFTEQNSGLIYRGQSGGMNEAF.
3. The peptide of claim 2 wherein the peptide is selected from the group consisting of
(a) VSHGFTEQN (Sequence ID No:2);
(b) HGFTEQNSG (Sequence ID No:3);
(c) FTEQNSGLI (Sequence ID No:4);
(d) EQNSGLIYR (Sequence ID No:5);
(e) NSGLIYRGO (Sequence ID No:6);
(f) GLIYRGQSG (Sequence ID No:7);
(g) IYRGQSGGM (Sequence ID No:8);
(h) RGQSGGMNE (Sequence ID No:9);
(i) QSGGMNEAF (Sequence ID No:10).
4. A peptide comprising the amino acid sequence HGFTEQNSG.
5. A peptide comprising the amino sequence
SGALRYMDQPSRDGRSIDM (Sequence ID No:11)
or a fragment or analogue thereof.
6. The peptide of claim 5 wherein the peptide has an amino acid sequence comprising about nine consecutive amino acids from the amino acid sequence
SGALRYMDQPSRDGRSIDM.
7. The peptide of claim 6 wherein the peptide is selected from the group consisting of
(a) SGALRYMDQ (Sequence ID No:12);
(b) ALRYMDQPS (Sequence ID No:13);
(c) RYMDQPSRD (Sequence ID No:14);
(d) MDQPSRDGR (Sequence ID No:15)
(e) QPSRDGRSI (Sequence ID No:16);
(f) SRDGRSIDM (Sequence ID No:17).
8. A peptide comprising the amino acid sequence RYMDQPSRD.
9. An immunogenic composition comprising at least one active component selected from the group consisting of:
(a) a peptide comprising the amino acid sequence HGFTEQNSG;
(b) a peptide comprising the amino acid sequence RYMDQPSRD;
(c) a peptide comprising the amino acid sequence VSHGFTEQNSGLIYRGQSGGMNEAF;
(d) a peptide comprising the amino acid sequence SGALRYMDQPSRDGRSIDM;
(e) a fragment or analogue of a peptide of (a), (b), (c) or (d);
(f) a purified and isolated nucleic acid molecule encoding a peptide of (a), (b), (c) or (d); and
(g) a nucleotide sequence which hybridises under stringent conditions to any of the nucleic acid molecules of (f)
and a pharmaceutically acceptable carrier, said at least one active component producing an immune response when administered to a host.
10. The immunogenic composition of claim 9 formulated as a vaccine for administration to a mammal to protect the mammal against a disease caused by a bacterial pathogen which secretes a zinc metalloprotease.
11. The immunogenic composition of claim 10 wherein the bacterial pathogen secretes a thermolysin-like metalloprotease.
12. The immunogenic composition of claim 10 wherein the mammal is to be protected against a disease caused by a pathogen selected from the group consisting of P. aeruginosa, B. cepacia, Vibrio cholerae, V. vulnificus, Legionella pneumophila, Serratia marcescens, Bacillus anthracis, Clostridium tetani, Clostridium botulinum, Aeromonas hydrophila, Staphylococcus epidermidis, Staphylococous aureus, Streptococcus sanguis, Streptococcus faecalis, Lysteria monocytogenes, and Pasteurella haemolytica.
13. The immunogenic composition of claim 12 wherein the at least one active component is selected from the group consisting of
(a) the peptide HGFTEQNSG;
(b) the peptide RYMDQPSRD; and
(c) a mixture of the peptide HGFTEQNSG and the peptide RYMDQPSRD.
14. The immunogenic composition of claim 13 wherein the peptide is conjugated to a carrier protein.
15. The immunogenic composition of claim 14 wherein the carrier protein is selected from the group consisting of keyhole limpet haemocyanin, diphtheria toxoid, diphtheria toxin CRM197, tetanus toxoid, P. aeruginosa exotoxin A mutant form, cholera toxin B subunit, pertussis toxin subunits, measles virus F protein and Haemophilus PRP outer membrane protein.
16. A method of protecting a susceptible host against a disease caused by a bacterial pathogen which secretes a zinc metalloprotease, said method comprising administering to the host an effective amount of the immunogenic composition of claim 9 .
17. The method of claim 16 wherein the bacterial pathogen is selected from the group consisting of P. aeruginosa, B. cepacia, Vibrio cholerae, V. vulnificus, Legionella pneumophila, Serratia marcescens, Bacillus anthracis, Clostridium tetani, Clostridium botulinum, Aeromonas hydrophila, Staphylococcus epidermidis, Staphylococous aureus, Streptococcus sanguis, Streptococcus faecalis, Lysteria monocytogenes, and Pasteurella haemolytica.
18. The method of claim 17 wherein the host is a human.
19. A method of protecting a susceptible host against a disease caused by a bacterial pathogen which secretes a zinc metalloprotease, said method comprising administering to the host an effective amount of the immunogenic composition of claim 13 .
20. The method of claim 19 wherein the bacterial pathogen is selected from the group consisting of P. aeruginosa, B. cepacia, Vibrio cholerae, V. vulnificus, Legionella pneumophila, Serratia marcescens, Bacillus anthracis, Clostridium tetani, Clostridium botulinum, Aeromonas hydrophila, Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus sanguis, Streptococcus faecalis, Lysteria monocytogenes, and Pasteurella haemolytica.
21. The method of claim 20 wherein the host is a human.
22. An antibody or antiserum specific for a peptide selected from the group consisting of
(a) VSHGFTEQNSGLIYRGQSGGMNEAF;
(b) SGALRYMDQPSRDGRSIDM;
(c) HGFTEQNSG;
(d) RYMDQPSRD; and
(e) a fragment or analogue of a peptide of (a), (b), (c) or (d).
23. A purified isolated nucleic acid molecule encoding a peptide selected from the group consisting of
(a) VSHGFTEQNSGLIYRGQSGGMNEAF;
(b) SGALRYMDQPSRDGRSIDM;
(c) HGFTEQNSG;
(d) RYMDQPSRD; and
(e) a fragment or analogue of a peptide of (a), (b), (c) or (d).
24. A method of producing a vaccine comprising administering the immunogenic composition of claim 9 to a test host to determine an amount and a frequency of administration of the active component to confer protection against a disease caused by a bacterial pathogen which secretes a zinc metalloprotease, and formulating the active component in a form suitable for administration to a host to be treated in accordance with said determined amount and frequency of administration.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/988,019 US20020102277A1 (en) | 1996-12-20 | 2001-11-16 | Conserved metalloprotease epitopes |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/772,282 US6270777B1 (en) | 1996-12-20 | 1996-12-20 | Conserved metalloprotease epitopes |
US27541799A | 1999-03-24 | 1999-03-24 | |
US09/988,019 US20020102277A1 (en) | 1996-12-20 | 2001-11-16 | Conserved metalloprotease epitopes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US27541799A Division | 1996-12-20 | 1999-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020102277A1 true US20020102277A1 (en) | 2002-08-01 |
Family
ID=25094541
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/772,282 Expired - Fee Related US6270777B1 (en) | 1996-12-20 | 1996-12-20 | Conserved metalloprotease epitopes |
US09/988,019 Abandoned US20020102277A1 (en) | 1996-12-20 | 2001-11-16 | Conserved metalloprotease epitopes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/772,282 Expired - Fee Related US6270777B1 (en) | 1996-12-20 | 1996-12-20 | Conserved metalloprotease epitopes |
Country Status (2)
Country | Link |
---|---|
US (2) | US6270777B1 (en) |
CA (1) | CA2202322A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070105799A1 (en) * | 2002-09-10 | 2007-05-10 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection |
US20090053248A1 (en) * | 2002-05-31 | 2009-02-26 | Thomas Jefferson University | Compositions and methods for transepithelial molecular transport |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
GB0020953D0 (en) * | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
US20040202648A1 (en) * | 2003-04-04 | 2004-10-14 | Cabezon Teresa Elisa Virgina Silva | Vaccines |
US7736910B2 (en) * | 2005-10-04 | 2010-06-15 | Calypte Biomedical Corporation | One-step production of gold sols |
EP1988163B1 (en) | 2006-02-22 | 2012-06-27 | International Institute of Cancer Immunology, Inc. | Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02104285A (en) * | 1988-08-26 | 1990-04-17 | Suntory Ltd | Dna coding elastase from pseudomonas aeruginosa |
CA1340530C (en) * | 1989-04-28 | 1999-05-04 | Kok Kheong Lee | Synthetic pseudomonas aeruginosa pilin peptide and related vaccines and diagnostics |
ATE364621T1 (en) * | 1992-03-06 | 2007-07-15 | Innogenetics Nv | HIV PEPTIDES |
-
1996
- 1996-12-20 US US08/772,282 patent/US6270777B1/en not_active Expired - Fee Related
-
1997
- 1997-04-10 CA CA002202322A patent/CA2202322A1/en not_active Abandoned
-
2001
- 2001-11-16 US US09/988,019 patent/US20020102277A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090053248A1 (en) * | 2002-05-31 | 2009-02-26 | Thomas Jefferson University | Compositions and methods for transepithelial molecular transport |
US20070105799A1 (en) * | 2002-09-10 | 2007-05-10 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection |
Also Published As
Publication number | Publication date |
---|---|
US6270777B1 (en) | 2001-08-07 |
CA2202322A1 (en) | 1998-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11572391B2 (en) | Antibodies for prevention, treatment and diagnosis of P. gingivalis infection | |
JP2907552B2 (en) | Haemophilus outer membrane protein | |
US6994859B1 (en) | Biologically active, hemagglutinin from type A Clostridium botulinum and methods of use | |
EP1379550B1 (en) | A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences | |
ES2270420T3 (en) | HAEMOPHILUS TRANSFERRINE RECEPTING GENES. | |
US5468484A (en) | Method of prevention of pseudomonas infection | |
KR100356040B1 (en) | Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with porphyromonas gingivalis | |
JPH09501059A (en) | Tbp2 fragment of the meningococcal transferrin receptor | |
US6270777B1 (en) | Conserved metalloprotease epitopes | |
CA2148563C (en) | Purified nontypable haemophilus influenzae p5 protein as a vaccine for nontypable haemophilus influenzae strain | |
JP2012526059A (en) | Polypeptides from enterococci and their use for vaccination | |
JP2001510683A (en) | Pseudomonas exotoxin A-like chimeric immunogen | |
CA2069106A1 (en) | Chimeric proteins | |
US6461618B1 (en) | 74 kilodalton outer membrane protein from moraxella catarrhalis | |
US20050002956A1 (en) | Vaccine | |
KR20070001274A (en) | Therapeutic peptides | |
US7033799B2 (en) | Haemophilus adherence and penetration proteins | |
US6218147B1 (en) | Haemophilus adhesin protein | |
US6827936B1 (en) | Synthetic peptide vaccines for dental caries | |
JP3516688B2 (en) | Transferrin receptor gene | |
EP2915543B1 (en) | Polypeptides derived from Enterococcus and their use for vaccination and the generation of therapeutic antibodies | |
KR100394454B1 (en) | Transferrin receptor genes | |
KR100461710B1 (en) | Novel Pseudomonas aeruginosa cell membrane protein gene and vaccine for preventing Pseudomonas aeruginosa infection using the same | |
AU2013203249A1 (en) | Prevention, treatment and diagnosis of P.gingivalis infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |